

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number
WO 2004/006927 A2

(51) International Patent Classification⁷: **A61K 31/445**,
A61P 37/00, C07D 401/12, 239/26, 211/96

(21) International Application Number:
PCT/GB2003/002985

(22) International Filing Date: 9 July 2003 (09.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0216382.2 13 July 2002 (13.07.2002) GB

(71) Applicant (for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GB, GD, GE, GH, GM, GR, HR, HU, ID, IE, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, SZ, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW only): **ASTRAZENECA AB** [SE/SE]; Sodertalje, S-151 85 (SE).

(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BURROWS, Jeremy, Nicholas** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

TUCKER, Howard [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **BROWN, Simon, James** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **PATEL, Ian** [GB/GB]; Avlon Works, Severn Road, Hallen, Bristol, Avon BS10 7ZE (GB).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **COMPOUNDS**

(57) Abstract: A compound of formula (1): wherein B is optionally substituted C₂₋₄alkenyl or C₂₋₄alkynyl; useful in the inhibition of one or more metalloproteinases and in particular TACE.

WO 2004/006927 A2

COMPOUNDS

The present invention relates to compounds useful in the inhibition of metalloproteinases and in particular to pharmaceutical compositions comprising them, as well
5 as their use.

The compounds of this invention are inhibitors of one or more metalloproteinase enzymes and are particularly effective as inhibitors of TACE (TNF α Converting Enzyme). Metalloproteinases are a superfamily of proteinases (enzymes) whose numbers in recent years have increased dramatically. Based on structural and functional considerations these enzymes
10 have been classified into families and subfamilies as described in N.M. Hooper (1994) FEBS Letters 354:1-6. Examples of metalloproteinases include the matrix metalloproteinases (MMP) such as the collagenases (MMP1, MMP8, MMP13), the gelatinases (MMP2, MMP9), the stromelysins (MMP3, MMP10, MMP11), matrilysin (MMP7), metalloelastase (MMP12), enamelysin (MMP19), the MT-MMPs (MMP14, MMP15, MMP16, MMP17); the reprolysin
15 or adamalysin or MDC family which includes the secretases and sheddases such as TNF converting enzymes (ADAM10 and TACE); the astacin family which include enzymes such as procollagen processing proteinase (PCP); and other metalloproteinases such as aggrecanase, the endothelin converting enzyme family and the angiotensin converting enzyme family.

20 Metalloproteinases are believed to be important in a plethora of physiological disease processes that involve tissue remodelling such as embryonic development, bone formation and uterine remodelling during menstruation. This is based on the ability of the metalloproteinases to cleave a broad range of matrix substrates such as collagen, proteoglycan and fibronectin. Metalloproteinases are also believed to be important in the processing, or secretion, of
25 biologically important cell mediators, such as tumour necrosis factor (TNF); and the post translational proteolysis processing, or shedding, of biologically important membrane proteins, such as the low affinity IgE receptor CD23 (for a more complete list see N. M. Hooper *et al.*, (1997) Biochem J. 321:265-279).

Metalloproteinases have been associated with many disease conditions. Inhibition of
30 the activity of one or more metalloproteinases may well be of benefit in these disease conditions, for example: various inflammatory and allergic diseases such as, inflammation of the joint (especially rheumatoid arthritis, osteoarthritis and gout), inflammation of the gastro-

intestinal tract (especially inflammatory bowel disease, ulcerative colitis and gastritis), inflammation of the skin (especially psoriasis, eczema and dermatitis); in tumour metastasis or invasion; in disease associated with uncontrolled degradation of the extracellular matrix such as osteoarthritis; in bone resorptive disease (such as osteoporosis and Paget's disease)); in diseases associated with aberrant angiogenesis; the enhanced collagen remodelling associated with diabetes, periodontal disease (such as gingivitis), corneal ulceration, ulceration of the skin, post-operative conditions (such as colonic anastomosis) and dermal wound healing; demyelinating diseases of the central and peripheral nervous systems (such as multiple sclerosis); Alzheimer's disease; and extracellular matrix remodelling observed in cardiovascular diseases such as restenosis and atherosclerosis.

A number of metalloproteinase inhibitors are known; different classes of compounds may have different degrees of potency and selectivity for inhibiting various metalloproteinases. We have discovered a class of compounds that are inhibitors of metalloproteinases and are of particular interest in inhibiting TACE. The compounds of this invention have beneficial potency and/or pharmacokinetic properties.

TACE (also known as ADAM17) which has been isolated and cloned [R.A. Black *et al.* (1997) *Nature* 385:729-733; M.L. Moss *et al.* (1997) *Nature* 385:733-736] is a member of the adamalysin family of metalloproteins. TACE has been shown to be responsible for the cleavage of pro-TNF α , a 26kDa membrane bound protein to release 17kDa biologically active soluble TNF α . [Schlondorff *et al.* (2000) *Biochem. J.* 347: 131-138]. TACE mRNA is found in most tissues, however TNF α is produced primarily by activated monocytes, macrophages and T lymphocytes. TNF α has been implicated in a wide range of pro-inflammatory biological processes including induction of adhesion molecules and chemokines to promote cell trafficking, induction of matrix destroying enzymes, activation of fibroblasts to produce prostaglandins and activation of the immune system [Aggarwal *et al* (1996) *Eur. Cytokine Netw.* 7: 93-124]. Clinical use of the anti-TNF biologicals has shown TNF α to play an important role in a range of inflammatory diseases including rheumatoid arthritis, Crohn's disease and psoriasis [Onrust *et al* (1998) *Biodrugs* 10: 397-422, Jarvis *et al* (1999) *Drugs* 57:945-964]. TACE activity has also been implicated in the shedding of other membrane bound proteins including TGF α , p75 & p55 TNF receptors, L-selectin and amyloid precursor protein [Black (2002) *Int. J. Biochem. Cell Biol.* 34: 1-5]. The biology of TACE inhibition has recently been reviewed and shows TACE to have a central role in TNF α production and


selective TACE inhibitors to have equal, and possibly greater, efficacy in the collagen induced arthritis model of RA than strategies that directly neutralise TNF α [Newton et al (2001) Ann. Rheum. Dis. 60: iii25-iii32].

A TACE inhibitor might therefore be expected to show efficacy in all disease where TNF α has been implicated including, but not limited to, inflammatory diseases including rheumatoid arthritis and psoriasis, autoimmune diseases, allergic/atopic diseases, transplant rejection and graft versus host disease, cardiovascular disease, reperfusion injury, malignancy.

Compounds that inhibit matrix metalloproteinases are already known in the art. WO 00/12477 discloses hydroxamic acids and carboxylic acid derivatives that are inhibitors of matrix metalloproteinases; WO 00/12478 discloses arylpiperazines that are useful in the inhibition of matrix metalloproteinase and are of particular interest as regards the inhibition of MMP13 and MMP9; and WO 01/87870 discloses hydroxamic acid derivatives which are inhibitors of matrix metalloproteinases including ADAM or ADAM-TS enzymes.

Surprisingly we have found a series of sulphonylpiperidine compounds comprising an alkenyl or alkynyl substituents which have metalloproteinase inhibitory activity, and are in particular, inhibitors of TACE (ADAM17).

According to one aspect of the present invention there is provided a compound of formula (1):



formula (1)

wherein Z is selected from $-\text{CONR}^{15}\text{OH}$ and $-\text{N}(\text{OH})\text{CHO}$;

R^{15} is hydrogen or C_{1-3} alkyl;

wherein R^1 is hydrogen or a group selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_3 -cycloalkyl, C_{5-7} cycloalkenyl, aryl, heteroaryl and heterocyclyl where the group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-6} cycloalkyl (optionally substituted by one or more R^{17}), aryl (optionally substituted by one or more R^{17}),

heteroaryl (optionally substituted by one or more R^{17}), heterocyclyl, C_{1-4} alkoxycarbonyl, $-OR^5$, $-SR^2$, $-SOR^2$, $-SO_2R^2$, $-COR^2$, $-CO_2R^5$, $-CONR^5R^6$, $-NR^{16}COR^5$, $-SO_2NR^5R^6$ and $-NR^{16}SO_2R^2$;

R^{16} is hydrogen or C_{1-3} alkyl;

5 R^{17} is selected from halo, C_{1-6} alkyl, C_{3-6} cycloalkyl and C_{1-6} alkoxy;

R^2 is group selected from C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{5-7} cycloalkenyl, heterocycloalkyl, aryl, heteroaryl, aryl C_{1-4} alkyl and heteroaryl C_{1-4} alkyl where the group is optionally substituted by one or more halo;

R^5 is hydrogen or a group selected from C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{5-7} cycloalkenyl,

10 heterocycloalkyl, aryl, heteroaryl, aryl C_{1-4} alkyl and heteroaryl C_{1-4} alkyl where the group is optionally substituted by one or more halo;

R^6 is hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl;

or R^5 and R^6 together with the nitrogen to which they are attached form a heterocyclic 4- to 7-membered ring;

15 wherein R^8 is hydrogen or a group selected from C_{1-6} alkyl, C_{3-7} cycloalkyl and heterocyclyl where the group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy and C_{1-4} alkyl;

or R^1 and R^8 together form a carbocyclic or saturated heterocyclic 3- to 6-membered ring;

wherein R^3 and R^4 are independently hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{5-7} cycloalkenyl,

20 heterocyclyl, aryl or heteroaryl;

wherein n is 0 or 1;

wherein m is 0 or 1;

wherein D is hydrogen, C_{1-4} alkyl, C_{3-6} cycloalkyl or fluoro;

wherein X is $-(CR^9R^{10})-Q-(CR^{11}R^{12})_u-$ where u is 0 or 1;

25 Q is O, S, SO or SO_2 ;

R^9 , R^{10} , R^{11} and R^{12} are independently selected from hydrogen, C_{1-4} alkyl and C_{3-6} cycloalkyl;

wherein B is C_{2-4} alkenyl or C_{2-4} alkynyl, each being optionally independently substituted by a group selected from C_{1-4} alkyl, C_{3-6} cycloalkyl, heterocycloalkyl, aryl, heteroaryl, heterocyclyl

whereby the group is optionally substituted by one or more halo, nitro, cyano, trifluoromethyl,

30 trifluoromethoxy, $-CONHR^{13}$, $-CONHR^{13}R^{14}$, $-SO_2R^{13}$, $-SO_2NHR^{13}$, $-SO_2NR^{13}R^{14}$, $-$

$NHSO_2R^{13}$, C_{1-4} alkyl and C_{1-4} alkoxy;

R^{13} and R^{14} are independently hydrogen, C_{1-4} alkyl or C_{3-5} cycloalkyl;

or R¹³ and R¹⁴ together with the nitrogen to which they are attached form a heterocyclic 4 to 7-membered ring.

Another aspect, the invention relates to compounds of formula (1) as hereinabove
5 defined or to a pharmaceutically acceptable salt thereof.

It is to be understood that, insofar as certain of the compounds of formula (1) defined
above may exist in optically active or racemic forms by virtue of one or more asymmetric
carbon or sulphur atoms, the invention includes in its definition any such optically active or
racemic form which possesses metalloproteinases inhibition activity and in particular TACE
10 inhibition activity. The synthesis of optically active forms may be carried out by standard
techniques of organic chemistry well known in the art, for example by synthesis from optically
active starting materials or by resolution of a racemic form. Similarly, the above-mentioned
activity may be evaluated using the standard laboratory techniques referred to hereinafter.

Compounds of formula (1) are therefore provided as enantiomers, diastereomers,
15 geometric isomers and atropisomers.

Within the present invention it is to be understood that a compound of formula (1) or a
salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings
within this specification can represent only one of the possible tautomeric forms. It is to be
understood that the invention encompasses any tautomeric form which has metalloproteinases
20 inhibition activity and in particular TACE inhibition activity and is not to be limited merely to
any one tautomeric form utilised within the formulae drawings. The formulae drawings
within this specification can represent only one of the possible tautomeric forms and it is to be
understood that the specification encompasses all possible tautomeric forms of the compounds
drawn not just those forms which it has been possible to show graphically herein.

It is also to be understood that certain compounds of formula (1) and salts thereof can
25 exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be
understood that the invention encompasses all such solvated forms which have
metalloproteinases inhibition activity and in particular TACE inhibition activity.

It is also to be understood that certain compounds of formula (1) may exhibit
30 polymorphism, and that the invention encompasses all such forms which possess
metalloproteinases inhibition activity and in particular TACE inhibition activity.

The present invention relates to the compounds of formula (1) as hereinbefore defined as well as to the salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula (1) and their pharmaceutically acceptable salts. Pharmaceutically acceptable salts of the invention may, for example, include acid addition salts of the compounds of formula (1) as hereinbefore defined which are sufficiently basic to form such salts. Such acid addition salts include but are not limited to hydrochloride, hydrobromide, citrate and maleate salts and salts formed with phosphoric and sulphuric acid. In addition where the compounds of formula (1) are sufficiently acidic, salts are base salts and examples include but are not limited to, an alkali metal salt for example sodium or potassium, an alkaline earth metal salt for example calcium or magnesium, or organic amine salt for example triethylamine or tris-(2-hydroxyethyl)amine

The compounds of formula (1) may also be provided as *in vivo* hydrolysable esters. An *in vivo* hydrolysable ester of a compound of formula (1) containing carboxy or hydroxy group is, for example a pharmaceutically acceptable ester which is cleaved in the human or animal body to produce the parent acid or alcohol. Such esters can be identified by administering, for example, intravenously to a test animal, the compound under test and subsequently examining the test animal's body fluid.

Suitable pharmaceutically acceptable esters for carboxy include C₁₋₆alkoxymethyl esters for example methoxymethyl, C₁₋₆alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C₃₋₈cycloalkoxycarbonyloxyC₁₋₆alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C₁₋₆alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.

Suitable pharmaceutically-acceptable esters for hydroxy include inorganic esters such as phosphate esters (including phosphoramidic cyclic esters) and α -acyloxyalkyl ethers and related compounds which as a result of the *in vivo* hydrolysis of the ester breakdown to give the parent hydroxy group/s. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxymethoxy. A selection of *in vivo* hydrolysable ester forming groups for hydroxy include C₁₋₁₀alkanoyl, for example formyl, acetyl; benzoyl; phenylacetyl; substituted benzoyl and phenylacetyl, C₁₋₁₀alkoxycarbonyl (to give alkyl carbonate esters), for

example ethoxycarbonyl; di-(C₁₋₄)alkylcarbamoyl and *N*-(di-(C₁₋₄)alkylaminoethyl)-*N*-(C₁₋₄)alkylcarbamoyl (to give carbamates); di-(C₁₋₄)alkylaminoacetyl and carboxyacetyl.

Examples of ring substituents on phenylacetyl and benzoyl include aminomethyl, (C₁₋₄)alkylaminomethyl and di-((C₁₋₄)alkyl)aminomethyl, and morpholino or piperazino linked

5 from a ring nitrogen atom via a methylene linking group to the 3- or 4- position of the benzoyl ring. Other interesting *in vivo* hydrolysable esters include, for example, R^AC(O)O(C₁₋₆)alkyl-CO-, wherein R^A is for example, benzyloxy-(C₁₋₄)alkyl, or phenyl). Suitable substituents on a phenyl group in such esters include, for example, 4-(C₁₋₄)piperazino-(C₁₋₄)alkyl, piperazino-(C₁₋₄)alkyl and morpholino-(C₁₋₄)alkyl.

10 In this specification the generic term "alkyl" includes both straight-chain and branched-chain alkyl groups. However references to individual alkyl groups such as "propyl" are specific for the straight chain version only and references to individual branched-chain alkyl groups such as *tert*-butyl are specific for the branched chain version only. For example, "C₁₋₃alkyl" includes methyl, ethyl, propyl and isopropyl, examples of "C₁₋₄alkyl" include the
15 examples of "C₁₋₃alkyl", butyl and *tert*-butyl and examples of "C₁₋₆alkyl" include the examples of "C₁₋₄alkyl" and additionally pentyl, 2,3-dimethylpropyl, 3-methylbutyl and hexyl. Examples of "C₁₋₂₀alkyl" include the examples of "C₁₋₆alkyl" and other straight chain and branched alkyl groups. An analogous convention applies to other generic terms, for example "C₂₋₄alkenyl" includes vinyl, allyl and 1-propenyl and examples of "C₂₋₆alkenyl" include the
20 examples of "C₂₋₄alkenyl" and additionally 1-butenyl, 2-butenyl, 3-butenyl, 2-methylbut-2-enyl, 3-methylbut-1-enyl, 1-pentenyl, 3-pentenyl and 4-hexenyl. Examples of "C₂₋₄alkynyl" includes ethynyl, 1-propynyl and 2-propynyl and examples of "C₂₋₆alkynyl" include the examples of "C₂₋₄alkynyl" and additionally 3-butyne, 2-pentyne and 1-methylpent-2-ynyl.

The term "C₃₋₆cycloalkyl" includes cyclopropyl, cyclobutyl, cyclopentyl and
25 cyclohexyl. The term "C₃₋₇cycloalkyl" includes "C₃₋₆cycloalkyl" and additionally cycloheptyl. The term "C₃₋₁₀cycloalkyl" includes "C₃₋₇cycloalkyl" and additionally cyclooctyl, cyclononyl and cyclodecyl.

"Heterocycloalkyl" is a monocyclic saturated 3- to 10-membered ring containing 1 or 2 heteroatoms selected from nitrogen, sulphur or oxygen wherein a ring nitrogen or sulphur
30 may be oxidised to the N-oxide or S-oxide(s).

"C₅₋₇cycloalkenyl" is a monocyclic 5 to 7-membered ring containing 1, 2 or 3 double bonds. Examples are cyclopentenyl and cyclohexenyl.

The term "halo" refers to fluoro, chloro, bromo and iodo.

Examples of "C₁₋₄alkoxy" include methoxy, ethoxy, propoxy and isopropoxy.

Examples of "C₁₋₆alkoxy" include the examples of "C₁₋₄alkoxy" and additionally pentyloxy, 1-ethylpropoxy and hexyloxy. Examples of "C₁₋₄alkoxycarbonyl" include methoxycarbonyl,

5 ethoxycarbonyl, propoxycarbonyl and isopropoxycarbonyl.

Examples of "aryl" are phenyl and naphthyl.

Examples of "arylC₁₋₄alkyl" are benzyl, phenylethyl, naphthylmethyl and naphthylethyl.

"Heteroaryl" is monocyclic or bicyclic aryl ring containing 5 to 10 ring atoms of which
10 1, 2, 3 or 4 ring atoms are chosen from nitrogen, sulphur or oxygen where a ring nitrogen may be oxidised. Examples of heteroaryl are pyridyl, imidazolyl, quinolinyl, cinnolyl, pyrimidinyl, thienyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, isoxazolyl and pyrazinyl. Preferably heteroaryl is pyridyl, imidazolyl, quinolinyl, pyrimidinyl, thienyl, pyrazolyl, thiazolyl, oxazolyl and isoxazolyl.

15 Examples of "heteroarylC₁₋₄alkyl" are pyridylmethyl, pyridylethyl, pyrimidinylethyl, pyrimidinylpropyl, quinolinylpropyl and oxazolylmethyl.

"Heterocyclyl" is a saturated, partially saturated or unsaturated, monocyclic or bicyclic ring containing 4 to 12 atoms of which 1, 2, 3 or 4 ring atoms are chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen
20 linked, wherein a -CH₂- group can optionally be replaced by a -C(O)-; a ring nitrogen or sulphur atom may be optionally oxidised to form the N-oxide or S-oxide(s); and a ring -NH may be optionally substituted by acetyl, formyl, methyl or mesyl. Examples and suitable values of the term "heterocyclyl" are piperidinyl, *N*-acetylpiperidinyl, *N*-methylpiperidinyl, *N*-formylpiperazinyl, *N*-mesylpiperazinyl, homopiperazinyl, piperazinyl, azetidiny, oxetanyl,
25 morpholinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, indolinyl, pyranyl, dihydro-2*H*-pyranyl, tetrahydrofuran-2-yl, 2,2-dimethyl-1,3-dioxolanyl and 3,4-dimethylenedioxybenzyl. Preferred values are 3,4-dihydro-2*H*-pyran-5-yl, tetrahydrofuran-2-yl, 2,2-dimethyl-1,3-dioxolan-2-yl and 3,4-dimethylenedioxybenzyl.

Heterocyclic rings are rings containing 1, 2 or 3 rings atoms selected nitrogen, oxygen
30 and sulphur. "Heterocyclic 5 to 7-membered" rings are pyrrolidinyl, piperidinyl, piperazinyl, homopiperidinyl, homopiperazinyl, thiomorpholinyl, thiopyranyl and morpholinyl.

"Heterocyclic 4 to 7-membered" rings include the examples of "heterocyclic 5 to 7-membered" and additionally azetidiny.

"Saturated heterocyclic 3 to 6-membered" rings are oxiranyl, aziridiny, thiirane azetidiny, oxetanyl, thietanyl, tetrahydrothienyl, pyrrolidiny, tetrahydrofuranly, tetrahydro-
5 2H-pyranly, tetrahydro-2H-thiopyranly and piperidiny and a ring nitrogen may be substituted by a group selected from formyl, acetyl and mesyl.

A "carbocyclic 3 to 6-membered" ring is a saturated, partially saturated or unsaturated ring containing 3 to 6 ring carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclopent-3-enyl, cyclohexyl and cyclopent-2-enyl.

10 Where optional substituents are chosen from "one of more" groups or substituents it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups. Preferably "one or more" means "1, 2 or 3" and this is particularly the case when the group or substituent is halo. "One or more" may also means "1 or 2".

15 Compounds of the present invention have been named with the aid of computer software (ACD/Name version 5.09).

Preferred values of Z, R¹, R³, R⁴, R⁸, n, m, D, X and B are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined
20 hereinbefore or hereinafter.

In one aspect of the present invention there is provided a compound of formula (1) as depicted above wherein Z is -CONR¹⁵OH. In another aspect Z is -N(OH)CHO.

In one aspect of the invention R¹⁵ is hydrogen, methyl, ethyl or isopropyl. In another aspect R¹⁵ is hydrogen.

25 In one aspect of the invention R¹ is hydrogen or a group selected from C₁₋₆alkyl, C₂₋₆alkynyl, C₃₋₇cycloalkyl, C₅₋₇cycloalkenyl, aryl, heteroaryl and heterocyclyl where the group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, C₁₋₄alkyl, C₂₋₄alkenyl, C₃₋₆cycloalkyl (optionally substituted by R¹⁷), aryl (optionally substituted by R¹⁷), heteroaryl (optionally substituted by
30 R¹⁷), C₁₋₄alkoxycarbonyl, -OR⁵, -SR², -SOR², -SO₂R², -COR², -CO₂R⁵, -CONR⁵R⁶, -NR¹⁶COR⁵, -SO₂NR⁵R⁶ and -NR¹⁶SO₂R². In another aspect R¹ is hydrogen, C₁₋₆alkyl or aryl where C₁₋₆alkyl or aryl are optionally substituted by one or more substituents independently

-10-

selected from C₁₋₄alkyl, aryl (optionally substituted by R¹⁷) and heteroaryl (optionally substituted by R¹⁷). In a further aspect R¹ is aryl, C₁₋₆alkyl or C₁₋₆alkyl substituted by aryl or heteroaryl. In another aspect R¹ is methyl, ethyl, propyl, isobutyl or phenyl where each is optionally substituted by phenyl or pyrimidinyl. In yet another aspect R¹ is methyl, isobutyl, 5 phenyl, 2-phenylethyl or 3-pyrimidin-2-ylpropyl. In a further aspect R¹ is methyl, phenyl, phenylethyl or pyrimidin-2-ylpropyl.

In one aspect of the invention R¹⁶ is hydrogen, methyl or ethyl. In another aspect R¹⁶ is methyl or ethyl. In another aspect R¹⁶ is hydrogen.

In one aspect of the invention R¹⁷ is halo or C₁₋₄alkyl. In another aspect R¹⁷ is fluoro, 10 chloro, bromo or methyl. In another aspect R¹⁷ is fluoro or methyl.

In one aspect of the invention R² is a group selected from C₁₋₆alkyl, aryl and arylC₁₋₄alkyl where the group is optionally substituted by halo. In another aspect R² is a group selected from methyl, phenyl and benzyl where the group is optionally substituted by chloro. In one aspect of the invention R² is methyl.

15 In one aspect of the invention R⁵ is hydrogen or a group selected from C₁₋₆alkyl, aryl and arylC₁₋₄alkyl where the group is optionally substituted by halo. In another aspect R⁵ is hydrogen or a group selected from methyl, phenyl and benzyl where the group is optionally substituted by chloro.

In one aspect of the invention R⁸ is hydrogen, methyl, ethyl, propyl or isopropyl. In 20 another aspect R⁸ is hydrogen.

In one aspect of the invention R³ is hydrogen.

In one aspect of the invention R⁴ is hydrogen.

In one aspect of the invention n is 0. In another aspect n is 1.

In one aspect of the invention m is 0. In another aspect m is 1.

25 In one aspect of the invention D is hydrogen, methyl or fluoro. In another aspect D is hydrogen.

In one aspect of the invention X is -CR⁹R¹⁰-Q- or -CR⁹R¹⁰-Q-CR¹¹R¹²-. In another aspect of the invention X is -(CH₂)-Q- or -(CH₂)-Q-(CH₂)-. In a further aspect X is -(CH₂)-O- or -(CH₂)-O-(CH₂)-.

30 In one aspect of the invention u is 1. In another aspect u is 0.

In one aspect of the invention Q is O.

In one aspect of the invention R⁹ is hydrogen.

-11-

In one aspect of the invention R^{10} is hydrogen.

In one aspect of the invention R^{11} is hydrogen.

In one aspect of the invention R^{12} is hydrogen.

In one aspect of the invention B is C_{2-4} alkenyl or C_{2-4} alkynyl, each being optionally
 5 independently substituted by C_{1-4} alkyl, C_{3-6} cycloalkyl, aryl, heteroaryl or heterocycloalkyl. In
 another aspect B is C_{2-4} alkenyl or C_{2-4} alkynyl, each being optionally independently substituted
 by C_{1-4} alkyl, C_{3-6} cycloalkyl, or heterocycloalkyl. In a further aspect B is C_{2-4} alkenyl or C_{2-4}
 alkynyl, each being optionally independently substituted by C_{1-4} alkyl or aryl. In yet another
 aspect B is vinyl or ethynyl where each is optionally independently substituted by methyl,
 10 ethyl or phenyl. In yet a further aspect B is vinyl, ethynyl, prop-1-enyl, prop-1-ynyl, but-1-
 ynyl or 2-phenylvinyl. In a further aspect B is vinyl, ethynyl, prop-1-enyl, prop-1-ynyl or but-
 1-ynyl.

A preferred class of compound is of formula (1) wherein:

15 Z is $-N(OH)CHO$;

R^1 is hydrogen or a group selected from C_{1-6} alkyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{5-7}
 cycloalkenyl, aryl, heteroaryl and heterocyclyl where the group is optionally substituted by
 one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl,
 trifluoromethoxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{3-6} cycloalkyl (optionally substituted by R^{17}), aryl
 20 (optionally substituted by R^{17}), heteroaryl (optionally substituted by R^{17}), C_{1-4} alkoxycarbonyl,
 $-OR^5$, $-SR^2$, $-SOR^2$, $-SO_2R^2$, $-COR^2$, $-CO_2R^5$, $-CONR^5R^6$, $-NR^{16}COR^5$, $-SO_2NR^5R^6$ and $-$
 $NR^{16}SO_2R^2$;

R^{16} is hydrogen, methyl or phenyl;

R^{17} is halo or C_{1-4} alkyl;

25 R^2 is a group selected from C_{1-6} alkyl, aryl and aryl C_{1-4} alkyl where the group is
 optionally substituted by halo;

R^5 is hydrogen or a group selected from C_{1-6} alkyl, aryl and aryl C_{1-4} alkyl where the
 group is optionally substituted by halo;

R^8 is hydrogen, methyl, ethyl, propyl or isopropyl;

30 R^3 is hydrogen, methyl, ethyl or phenyl;

R^4 is hydrogen, methyl, ethyl or phenyl;

n is 0;

-12-

m is 1;

D is hydrogen, methyl or fluoro;

X is $-(CH_2)-O-$ or $-(CH_2)-O-(CH_2)-$; and

B is C_{2-4} alkenyl or C_{2-4} alkynyl, each being optionally independently substituted by C_{1-4} alkyl, C_{3-6} cycloalkyl, aryl, heteroaryl or heterocycloalkyl.

Another preferred class of compound is of formula (1) wherein:

Z is $-N(OH)CHO$;

R^1 is hydrogen, C_{1-6} alkyl or aryl where C_{1-6} alkyl or aryl are optionally substituted by one or more substituents independently selected from C_{1-4} alkyl, aryl (optionally substituted by R^{17}) and heteroaryl (optionally substituted by R^{17});

R^{17} is halo or C_{1-4} alkyl;

R^8 is hydrogen;

R^3 is hydrogen;

15 R^4 is hydrogen;

n is 0;

m is 1;

D is hydrogen, methyl or fluoro;

X is $-(CH_2)-O-$ or $-(CH_2)-O-(CH_2)-$; and

20 B is C_{2-4} alkenyl or C_{2-4} alkynyl, each being optionally independently substituted by C_{1-4} alkyl or aryl.

Another preferred class of compound is of formula (1) wherein:

Z is $-CONR^{15}OH$;

25 R^1 is hydrogen or a group selected from C_{1-6} alkyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{5-7} cycloalkenyl, aryl, heteroaryl and heterocyclyl where the group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{3-6} cycloalkyl (optionally substituted by R^{17}), aryl (optionally substituted by R^{17}), heteroaryl (optionally substituted by R^{17}), C_{1-4} alkoxycarbonyl, 30 $-OR^5$, $-SR^2$, $-SOR^2$, $-SO_2R^2$, $-COR^2$, $-CO_2R^5$, $-CONR^5R^6$, $-NR^{16}COR^5$, $-SO_2NR^5R^6$ and $-NR^{16}SO_2R^2$;

R^{15} is hydrogen, methyl, ethyl or isopropyl;

-13-

R¹⁶ is hydrogen, methyl or phenyl;

R¹⁷ is halo or C₁₋₄alkyl;

R² is a group selected from C₁₋₆alkyl, aryl and arylC₁₋₄alkyl where the group is optionally substituted by halo;

5 R⁵ is hydrogen or a group selected from C₁₋₆alkyl, aryl and arylC₁₋₄alkyl where the group is optionally substituted by halo;

R⁸ is hydrogen, methyl, ethyl, propyl or isopropyl;

R³ is hydrogen, methyl, ethyl or phenyl;

R⁴ is hydrogen, methyl, ethyl or phenyl;

10 n is 0;

m is 1;

D is hydrogen, methyl or fluoro;

X is -(CH₂)-O- or -(CH₂)-O-(CH₂)- ; and

B is C₂₋₄alkenyl or C₂₋₄alkynyl, each being optionally independently substituted by C₁₋₄alkyl, C₃₋₆cycloalkyl, aryl, heteroaryl or heterocycloalkyl.

Another preferred class of compound is of formula (1) wherein:

Z is -CONR¹⁵OH;

R¹ is hydrogen, C₁₋₆alkyl or aryl where C₁₋₆alkyl or aryl are optionally substituted by one or more substituents independently selected from C₁₋₄alkyl, aryl (optionally substituted by R¹⁷) and heteroaryl (optionally substituted by R¹⁷);

R¹⁷ is halo or C₁₋₄alkyl;

R¹⁵ is hydrogen, methyl, ethyl or isopropyl;

R⁸ is hydrogen;

25 R³ is hydrogen;

R⁴ is hydrogen;

n is 0;

m is 1;

D is hydrogen, methyl or fluoro;

30 X is -(CH₂)-O- or -(CH₂)-O-(CH₂)- ; and

B is C₂₋₄alkenyl or C₂₋₄alkynyl, each being optionally independently substituted by C₁₋₄alkyl or aryl.

Another preferred class of compound is of formula (1) wherein:

Z is $-\text{CONR}^{15}\text{OH}$ or $-\text{N}(\text{OH})\text{CHO}$;

R^{15} is hydrogen;

5 R^1 is methyl, ethyl, propyl, isobutyl or phenyl where each is optionally substituted by phenyl or pyrimidinyl;

R^8 is hydrogen;

R^3 is hydrogen;

R^4 is hydrogen;

10 n is 0;

m is 1;

D is hydrogen;

X is $-(\text{CH}_2)-\text{O}-$ or $-(\text{CH}_2)-\text{O}-(\text{CH}_2)-$; and

B is vinyl or ethynyl where each is optionally independently substituted by methyl,
15 ethyl or phenyl.

In another aspect of the invention, preferred compounds of the invention are any one of:


- (1-phenyl-2-([4-(prop-2-ynyloxy)piperidin-1-yl]sulphonyl)ethyl)hydroxyformamide;
- 20 2-([4-(allyloxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;
- 2-([4-(but-2-enyloxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;
- 2-([4-(but-2-ynyloxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;
- (2-([4-(pent-2-ynyloxy)piperidin-1-yl]sulphonyl)-1-phenylethyl)hydroxyformamide;
- 1-([4-(but-2-ynyloxy)piperidin-1-yl]sulphonyl)methyl)-3-phenylpropyl(hydroxy)formamide;
- 25 2-([4-(but-2-ynyloxy)piperidin-1-yl]sulphonyl)-1-methylethyl(hydroxy)formamide;
- 1-([4-(but-2-ynyloxy)piperidin-1-yl]sulphonyl)methyl)-4-pyrimidin-2-ylbutyl(hydroxy)formamide;
- 1-([4-([4-(but-2-ynyloxy)methyl]piperidin-1-yl]sulphonyl)methyl)-4-pyrimidin-2-ylbutyl(hydroxy)formamide; and
- 30 2-([4-([4-(but-2-ynyloxy)methyl]piperidin-1-yl]sulphonyl)-1-methylethyl(hydroxy)formamide.

Further preferred compounds of the invention are any one of :

- (R/S)-1-([4-(but-2-ynyloxy)piperidin-1-yl]sulphonyl)methyl)-4-pyrimidin-2-ylbutyl(hydroxy)formamide;
 (R/S)-1-([4-[(but-2-ynyloxy)methyl]piperidin-1-yl]sulphonyl)methyl)-4-pyrimidin-2-ylbutyl(hydroxy)formamide;
 5 (R/S)-2-([4-[(but-2-ynyloxy)methyl]piperidin-1-yl]sulphonyl)-1-methylethyl(hydroxy)formamide;
 2-(4-But-2-ynyloxymethylpiperidin-1-ylsulphonylmethyl)-4-methyl-pentanoic acid hydroxyamide;
 (R/S)-2-([4-[prop-2-enyloxy]piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;
 10 (R/S)-2-([4-[but-2-enyloxy]piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide; and
 (R/S)-2-([4-[3-phenyl-prop-2-enyloxy]piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide.

In another aspect the present invention provides a process for the preparation of a
 15 compound of formula (1) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof wherein Z is $-N(OH)CHO$, which process comprises the steps of:

- a) converting a hydroxylamine of formula (2) into a compound of formula (1);



Scheme 1

20 and thereafter if necessary:


- i) converting a compound of formula (1) into another compound of formula (1);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

Formylation may be suitably performed by adding a preformed mixture of acetic acid
 25 (8 equivalents) and formic acid (excess) to formula (2) in tetrahydrofuran or dichloromethane and stirring the solution for 15 hours at temperatures ranging from 0°C to room temperature followed by stirring in methanol. Alternatively a formylation method described in *J.Med.Chem.*, 2002, 45, 219 using trifluoroethylformate can be used.

This process may further comprise a process for the preparation of a hydroxylamine of formula (2):

- when n is 0 and R^4 is hydrogen (indicated as a compound of formula (2')), which process comprises:


5 b) converting an alkene of formula (3) into a hydroxylamine of formula (2') ;



Scheme 2

Suitable reagents for such a conversion include aqueous hydroxylamine in tetrahydrofuran under an argon atmosphere.

10 The alkene of formula (3) where R^8 is hydrogen can be prepared by the reaction of a compound of formula (4') with a compound of formula (5) under Wadsworth-Emmons or Peterson reaction conditions;




Scheme 3

15 Wadsworth-Emmons or Peterson reactions involve the forming of the anion of formula (4') with 2 equivalents of lithium bis(trimethylsilyl)amide, sodium hydride or lithium diisopropylamide in tetrahydrofuran at temperatures of -78°C to 0°C and reacting this with 1 equivalent of diethylchlorophosphate (Wadsworth Emmons) or 1 equivalent of trimethylsilyl chloride (Peterson). After 1 hour an aldehyde (1.1 equivalent) in tetrahydrofuran is added to
20 the resultant anion described and reacted at room temperature over 15 hours.

The alkene of formula (3) where R^8 is hydrogen can also be prepared by the reaction of a compound of formula (4') with a compound of formula (6) as illustrated by scheme 4;

-17-




Scheme 4

Suitable bases include lithium bis(trimethylsilyl)amide, sodium hydride or lithium diisopropylamide in tetrahydrofuran at temperatures of -78°C to 0°C to form the anion.

- 5 Suitable reducing agents for the reduction step include sodium borohydride in ethanol or borane-dimethylsulphide complex or borane-tetrahydrofuran complex in tetrahydrofuran at room temperature. Suitable dehydration reagents for the dehydration step include methanesulphonyl chloride or tosyl chloride and triethylamine in dichloromethane at room temperature.

- 10 The present invention provides a process for the preparation of a compound of formula (6) wherein R^1 is C_{1-6} alkyl substituted by aryl or heteroaryl where the aryl and heteroaryl groups are optionally substituted by one or more R^{17} . Such a process is outlined in the scheme below:



- 15 wherein C is aryl or heteroaryl each being optionally substituted by one or more R^{17} ; L is a suitable leaving group such as halo, tosyl, mesyl or triflate; Y is such that a zinc metal salt is formed i.e. Y is for example bromo or iodo; and z is an integer of 1 to 6 such that $(\text{---})_z$ represents C_{1-6} alkylene; it is to be understood that in this aspect of the invention R^1 is



represented by

so that the C_{1-6} alkyl group represented by $(\text{---})_z$ may be a

- 20 straight or branched chain. In another aspect of the invention $(\text{---})_z$ may represent C_{1-20} alkyl.


The reaction is performed under an inert atmosphere, which ensures consistent catalytic activity and in a non-protic solvent such as tetrahydrofuran. Suitable catalysts include nickel based and palladium (0) based catalysts. Preferable a palladium (0) based catalyst is used.

The palladium (0) based catalyst may be generated from palladium (II) based compounds when used in conjunction with a promoter such as triphenylphosphine.

A specific example of a compound of formula (6) is ethyl 4-(pyrimidin-2-yl)butanoate. This compound is formed by the reaction of 2-bromopyrimidine with 4-ethoxy-4-oxo-butylzinc bromide in the presence of bis(acetonitrile)palladium (II) chloride (2.5mmol) and triphenylphosphine in a non-protic solvent and under an inert atmosphere. The stoichiometric amount of zinc salt produced as a by-product can be removed from the reaction mixture by washing with an aqueous solution of ethylenediamine tetraacetic acid tetrasodium salt. Preferably the non-protic solvent is tetrahydrofuran. Preferably the inert atmosphere is a nitrogen atmosphere.


Alternatively a process for the preparation of a hydroxylamine of formula (2):

- when n is 0 (indicated as a compound of formula (2[#])) may comprise;
 - c) i) reacting a compound of formula (4'') (see scheme 13 for its preparation) with R¹COOR, R¹COCl or activated R¹COOR to yield a ketone of formula (7'') (where R is C₁₋₂₀alkyl e.g. methyl, ethyl or arylC₁₋₄alkyl e.g. benzyl);
 - ii) reducing the ketone of formula (7'') to yield an alcohol of formula (8'');
 - iii) converting -OH group of the alcohol of formula (8'') into a leaving group (L) such as a halide, mesylate, tosylate etc. (see compound of formula (9''));
 - iv) displacing the leaving group with aqueous hydroxylamine to yield a hydroxylamine of formula (2[#]);



Scheme 5

A ketone of formula (7'') may additionally be prepared by the process illustrated in scheme 6:




Scheme 6

- 5 The silyl group present in the compound of formula (30) can be removed by tetrabutylammonium fluoride. Suitable leaving groups (L) are halo, mesyl and tosyl. A suitable chlorinating agent is $POCl_3$. A compound of formula (7'') is prepared in the last stage by reacting the compound of formula (33) with the appropriate piperidine reagent.

Or a process for the preparation of a hydroxylamine of formula (2):

- 10 • when n is 1 and R^3 and R^4 are both hydrogen (indicated as a compound of formula (2**)) may further comprise:
- d) i) reacting a compound of formula (4'') with a compound of formula (10) (either an epoxide or equivalent) to yield an alcohol of formula (8**);
- ii) converting -OH group of the alcohol of formula (8**) into a leaving group
- 15 such as a halide, mesylate, tosylate etc. (see compound of formula (9**);
- iii) displacing the leaving group with aqueous hydroxylamine to yield a hydroxylamine of formula (2**);



Scheme 7

Suitable bases are lithium bis(trimethylsilyl)amide and lithium diisopropylamide at temperatures from -78°C to 0°C . Suitable leaving groups (L) are chloro, bromo, iodo,


- 5 methanesulphonyl and tosyl and these would be formed from the alcohol by treatment with methanesulphonyl chloride and pyridine in dichloromethane (mesylate), tosyl chloride and pyridine in dichloromethane (tosylate), triphenylphosphine and carbon tetrabromide (bromo); the chloro, bromo and iodo derivatives could also be prepared from the mesylate or tosylate by addition of a suitable halide source, e.g. tetrabutylammonium iodide or sodium iodide or
- 10 lithium chloride in a solvent such as acetone.

Or a process for the preparation of a hydroxylamine of formula (2):

- when n is 1 and R⁸ is hydrogen, indicated as a compound of formula (2[^]), may further comprise:

- e)
 - i) reacting a compound of formula (4'') with a compound of formula (11) to yield an ester of formula (12[^]);
 - 15 ii) converting the ester of formula (12[^]) into an alcohol of formula (13[^]);
 - iii) displacing the -OH group with aqueous hydroxylamine to yield a hydroxylamine of formula (2[^]);

-21-




Scheme 8

The group -COOR of formula (12^A) is representative of an ester wherein R may be C₁₋₂₀ alkyl, e.g. methyl, ethyl or arylC₁₋₄alkyl, e.g. benzyl and B is a protecting group such as trimethylsilyl or tertiarybutyldimethylsilyl. Baeyer-Villiger reaction conditions such as a peracid e.g. *m*-CPBA (meta-chloroperbenzoic acid) in dichloromethane are suitable for the conversion of the ester group into the alcohol group. After the Baeyer-Villiger reaction, it will be necessary to remove the protecting group which is B in formula (12^A) and replace it with a B group as defined in relation to formula (1) as illustrated herein. It may be appropriate to convert the alcohol group into a leaving group such as bromo, iodo, mesyl and tosyl, before displacement with aqueous hydroxylamine.

In another aspect the present invention provides a process for the preparation of a compound of formula (1) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof wherein Z is -CONR¹⁵OH, which process comprises:

- a) converting an acid of formula (14) into a compound of formula (1);



Scheme 9

and thereafter if necessary:

- i) converting a compound of formula (1) into another compound of formula (1);


- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

The acid of formula (14) may be suitably activated by conversion to an acid halide, such as the acid chloride or to an activated ester using carbonyldiimidazole, a carbodiimide or a

- 5 pentafluorophenyl ester. Alternatively when the acid of formula (14) is an ester e.g. the methyl or ethyl ester, it can be converted directly to a compound of formula (1) by reaction with NHR^{15}OH .

Also provided is a process for the preparation of an acid of formula (14) which process comprises;

- 10 b) reacting a compound of formula (4'') with an alkene of formula (11) to yield an ester of formula (12[^]) which is hydrolysed to an acid of formula (14[']) where an acid of formula (14[']) is an acid of formula (14) wherein n is 1;




Scheme 10

- 15 Suitable bases able to deprotonate a compound of formula (4'') are butyllithium, lithium diisopropylamide and lithium bis(trimethylsilyl)amide followed by the addition of a copper salt e.g. copper bromide-dimethylsulphide complex, copper iodide, in solvents such as dimethylsulphide, ether, tetrahydrofuran at temperatures from -78°C to room temperature.

Or a process for the preparation of an acid of formula (14) comprises;


- 20 c) reacting a compound of formula (4'') with a compound of formula (15) to yield an acid of formula (14^{**}) which is an acid of formula (14) wherein n is 0, R^3 is hydrogen and R^4 is hydrogen;



Scheme 11

Suitable bases to deprotonate formula (4'') include lithium bis(trimethylsilyl)amide, lithium diisopropylamide and sodium hydride in solvents such as tetrahydrofuran and ether at temperatures from -78°C to 0°C .

- 5 In another aspect the present invention provides a process for the preparation of a compound of formula (1) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof wherein Z is $-\text{CONR}^{15}\text{OH}$, R^8 is hydrogen and n is 0; which process comprises steps as outlined in scheme 12:



Scheme 12

The process of scheme 12 comprises the steps of:

- reacting a thiol of formula (22) with an acrylate of formula (23) at temperatures of 0°C to 70°C to yield a thioether of formula (24);
- oxidising the thioether of formula (24) to a sulphonyl chloride of formula (25) by bubbling chlorine gas onto a solution of the thioether in acetic acid at temperatures of 0°C to room temperature;
- reacting the sulphonyl chloride of formula (25) with a piperidine of formula (26) under standard sulphonamide conditions (e.g. triethylamine in dichloromethane at temperatures from 0°C to 50°C) to yield a compound of formula (27);
- removing the protecting group to yield a compound of formula (1.)


The protecting group (PG) may be 2,4-dimethoxybenzyl which can be removed with mild acid (see Tetrahedron Letters, 1998, 39(43), 7865). The process of scheme 12 may further comprise if necessary:

- i) converting a compound of formula (1) into another compound of formula (1);
- 5 ii) removing any other protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

In another aspect of the invention, there is provided a process for the preparation of a compound of formula (4), formula (4') and formula (4'') which process comprises;

- 10 a) reacting a compound of formula (16) with a compound of formula (17) (wherein Q is O or S), in the presence of a base to deprotonate the compound of formula (17), to yield a compound of formula (18);
- b) removing the protecting group (PG) from the compound of formula (18) to yield a compound of formula (19);
- 15 c) reacting the compound of formula (19) with a suitable reagent to yield a compound of formula (4) wherein X is $-(CR^9R^{10})-Q-(CR^{11}R^{12})_u$; and
- d) oxidising Q where Q is S as required.

When R^4 is hydrogen a compound of formula (4') is produced and when R^3 and R^4 are both hydrogen compound of formula (4'') is produced




Scheme 13

Compounds of formula (4), formula (4') and formula (4'') may also be prepared by a process which comprises;

- a) reacting a compound of formula (20) (wherein Q is O or S) with a compound of formula (21), in the presences of a base to yield a compound of formula (18);
- 25

- b) removing the protecting group (PG) from the compound of formula (18) to yield a compound of formula (19);.
- c) reacting the compound of formula (19) with a suitable reagent to yield a compound of formula (4) wherein X is $-(CR^9R^{10})-Q-(CR^{11}R^{12})_u$; and
- 5 d) oxidising Q where Q is S as required.

When R^4 is hydrogen a compound of formula (4') is produced and when R^3 and R^4 are both hydrogen compound of formula (4'') is produced




Scheme 14

- 10 In both schemes 13 and 14; L is a suitable leaving group such as halo (chloro, bromo, iodo), mesyl, tosyl; suitable bases to deprotonate compounds of formula (17) and formula (20) include sodium hydride, lithium diisopropylamide, butyllithium and lithium bis(trimethylsilyl)amide; suitable reaction conditions for a) are temperatures ranging from -78°C to 70°C and an aprotic solvent, e.g. tetrahydrofuran under argon; suitable protecting
- 15 groups (PG) include Boc (t-butoxycarbonyl), CBz (carbonyloxybenzyl) groups and mesyl or another alkylsulphonyl. In the case where PG is alkylsulphonyl, reaction of formula (16) and (17) and of formula (20) and formula (21) directly produces a compound of formula (4). A compound of formula (18) can be converted to formula (19) by treatment with acid (Boc)
- boron trifluoride diethyl etherate in dichloromethane in the presence of dimethylsulphite
- 20 (CBz). A compound of formula (19) can be converted to a compound of formula (4) by treatment with an alkylsulphonyl chloride in the presence of a base such as pyridine in a solvent such as dichloromethane.

A compound of formula (1) can be prepared by removal of a protecting group on the

25 zinc binding group directly. The protecting group (PG) can be 2,4-dimethoxybenzyl which


can be removed with mild acid (see Tetrahedron Letters, 1998, 39(43), 7865). The required protected hydroxamic acid or reverse hydroxamate can be obtained by using a suitably protected hydroxylamine earlier in the synthesis.



Scheme 15

As discussed herein compounds that inhibit metalloproteinases and in particular TACE, are of great importance and it is thus apparent that any intermediate (and process for it
10 manufacture) involved in the manufacture of such a compound will be of commercial value.

One such metalloproteinase inhibitor and TACE inhibitor, disclosed herein, is (R/S)-1-
({[4-(but-2-ynyloxy)piperidin-1-yl]sulphonyl}methyl)-4-pyrimidin-2-
ylbutyl(hydroxy)formamide:




15 This compound can be made by a process that comprises the steps of :


- reacting 4-hydroxypiperidine with methanesulphonyl chloride in the presence of a base to yield 4-hydroxy-1-(methanesulphonyl)piperidine;
- adding a solution of 4-hydroxy-1-(methanesulphonyl)piperidine to sodium hydride, followed by addition of 1-bromobut-2-yne to yield 4-(but-2-ynyloxy)-1-methanesulphonylpiperidine;
- adding lithium bis(trimethylsilyl)amide to a solution of 4-(but-2-ynyloxy)-1-methanesulphonylpiperidine followed by ethyl 4-(pyrimidin-2-yl)butanoate to yield 1-{{[4-(but-2-ynyloxy)piperidinyl]sulphonyl}-5-(pyrimidin-2-yl)pentan-2-one;

- d) reducing 1-{{4-(but-2-ynyloxy)piperidiny]sulphonyl}-5-(pyrimidin-2-yl)pentan-2-one with a reagent such as sodium borohydride to yield (R/S)-1-{{4-(but-2-ynyloxy)piperidiny]sulphonyl}-5-(pyrimidin-2-yl)pentan-2-ol;
- e) dehydrating (R/S)-1-{{4-(but-2-ynyloxy)piperidiny]sulphonyl}-5-(pyrimidin-2-yl)pentan-2-ol using methanesulphonyl chloride to yield E-1-{{4-(but-2-ynyloxy)piperidiny]sulphonyl}-5-(pyrimidin-2-yl)pent-1-ene;
- f) reacting a solution of E-1-{{4-(but-2-ynyloxy)piperidiny]sulphonyl}-5-(pyrimidin-2-yl)pent-1-ene with hydroxylamine to yield (R/S)-[1-({[4-(4-but-2-ynyloxy)piperidin-1-yl]sulphonyl}methyl)-4-pyrimidin-2-ylbutyl]hydroxylamine;
- and
- g) adding a mixture of acetic anhydride and formic acid to a solution of (R/S)-[1-({[4-(4-but-2-ynyloxy)piperidin-1-yl]sulphonyl}methyl)-4-pyrimidin-2-ylbutyl]hydroxylamine to yield (R/S)-1-({[4-(but-2-ynyloxy)piperidin-1-yl]sulphonyl}methyl)-4-pyrimidin-2-ylbutyl(hydroxy)formamide.

A further embodiment of the invention thus provides ethyl 4-(pyrimidin-2-yl)butanoate, which is an intermediate used in the synthesis of (R/S)-1-({[4-(but-2-ynyloxy)piperidin-1-yl]sulphonyl}methyl)-4-pyrimidin-2-ylbutyl(hydroxy)formamide (see part c) of the above process).




Also provided is a process for the preparation of ethyl 4-(pyrimidin-2-yl)butanoate. This process uses Negishi coupling. Negishi coupling involves the cross coupling of an organozinc reagent with an aryl halide to form carbon-carbon bonds (Baba S., Negishi E., *J. Am. Chem. Soc.*, **1976**, 98, 6729-6731; Negishi E., King A., Okukado N., *J Org. Chem.*, **1977**, 42, 1821-1823).



Negishi coupling has several advantages over other coupling methods that employ organometal reagents other than organozinc reagents. Firstly it allows the direct coupling of

an sp^3 centre to an aryl group. Secondly, the organozinc reagent can be easily prepared from the corresponding organohalide, and finally the mild nature of organozinc reagents means that sensitive functional groups such as esters, ketones, nitriles and halides can be tolerated. For further details of Negishi coupling and other transition-metal catalysed cross coupling reactions, the reader is directed to Yamamoto Y., Negishi E., *J. Organomet. Chem.*, **1999**, 576, 1-317 and references cited therein and Tsuji J., *Palladium reagents and Catalysts*, Wiley, New York (1995) and references cited therein.

This process of the invention comprises the reaction of a 2-halopyrimidine, 2-tosylpyrimidine, 2-pyrimidinyl triflate or 2-pyrimidinyl mesylate with 4-ethoxy-4-oxo-butylzinc bromide or 4-ethoxy-4-oxo-butylzinc iodide in the presence of a catalyst;



wherein X is halo, triflate or mesylate and Y is bromide or iodide.

The process may further comprise the step of removing the zinc salt by-products by washing the crude resultant product with an aqueous solution of the tetrasodium salt of ethylenediamine tetraacetic acid. This step removes >99.9% of the zinc salt by-products.

It is preferred that the reaction is performed under an inert atmosphere to ensure consistent catalytic activity. It is also preferred that the reaction is performed in a non-protic solvent. Preferably the non-protic solvent is tetrahydrofuran, diethyl ether or dimethoxyethylglycol dimethylether and more preferably the solvent is tetrahydrofuran. Preferably the inert atmosphere is a nitrogen atmosphere.

Suitable catalysts for use in the process include nickel based and palladium (0) based catalysts. However it is preferred that a palladium (0) based catalyst is used. Preferably the palladium (0) based catalyst is generated by the action of a promoter such as triphenylphosphine on a palladium (II) based compound. More preferably the catalyst is generated from bis(acetonitrile) palladium (II) dichloride and triphenylphosphine.

A further aspect of the invention is the use of a pro catalyst comprising bis(acetonitrile) palladium (II) dichloride and triphenylphosphine in a Negishi coupling reaction.

2-Halopyrimidine, 2-tosylpyrimidine, 2-pyrimidinyl triflate and 2-pyrimidinyl mesylate are readily available or can be easily derived made by the skilled person from the art.

4-Ethoxy-4-oxo-butylzinc bromide is readily available and can, for example, be purchased from Rieke Metals Inc. who are known to use a reduction of zinc (II) cyanide with lithium and naphthalene for the preparation of their reagents (WO 93/15086). Alternatively 4-ethoxy-4-oxo-butylzinc bromide can be prepared from 4-bromobutyrate with diethylzinc and a manganese (II)/copper (I) catalyst system in DMPU (1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone) (I. Klement, P Knochel, *Tetrahedron Lett.*, 1994, 35, 1177 – the contents of which are incorporated herein by reference). 4-Ethoxy-4-oxo-butylzinc iodide can be similarly prepared but may also be made by the use of a zinc/copper couple activation reaction with chlorotrimethylsilane/1,2-dibromoethane (P. Knochel, M.C.P. Yeh, S.C. Berk, J. Talbert; *J. Org. Chem.*, 1988, 53, 2392) or the use of sonication (E. Erdik, *Tetrahedron*, 1987, 43, 2203)

It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogen group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.

It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard

practice (for illustration see T.W. Green, Protective Groups in Organic Synthesis, John Wiley and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.

A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *t*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *t*-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *tert*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

As stated hereinbefore the compounds defined in the present invention possesses
5 metalloproteinases inhibitory activity, and in particular TACE inhibitory activity. This property may be assessed, for example, using the procedure set out below.

Isolated Enzyme Assays

Matrix Metalloproteinase family including for example MMP13.

10 Recombinant human proMMP13 may be expressed and purified as described by Knauper *et al.* [V. Knauper *et al.*, (1996) The Biochemical Journal 271:1544-1550 (1996)]. The purified enzyme can be used to monitor inhibitors of activity as follows: purified proMMP13 is activated using 1mM amino phenyl mercuric acid (APMA), 20 hours at 21°C; the activated MMP13 (11.25ng per assay) is incubated for 4-5 hours at 35°C in assay buffer
15 (0.1M Tris-HCl, pH 7.5 containing 0.1M NaCl, 20mM CaCl₂, 0.02 mM ZnCl and 0.05% (w/v) Brij 35 using the synthetic substrate 7-methoxycoumarin-4-yl)acetyl.Pro.Leu.Gly.Leu.N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl.Ala.Arg.NH₂ in the presence or absence of inhibitors. Activity is determined by measuring the fluorescence at λ_{ex} 328nm and λ_{em} 393nm. Percent inhibition is calculated as follows: % Inhibition is equal
20 to the [Fluorescence_{plus inhibitor} - Fluorescence_{background}] divided by the [Fluorescence_{minus inhibitor} - Fluorescence_{background}].

A similar protocol can be used for other expressed and purified pro MMPs using substrates and buffers conditions optimal for the particular MMP, for instance as described in C. Graham Knight *et al.*, (1992) FEBS Lett. 296(3):263-266.

25 Adamalysin family including for example TNF convertase

The ability of the compounds to inhibit proTNF α convertase enzyme (TACE) may be assessed using a partially purified, isolated enzyme assay, the enzyme being obtained from the membranes of THP-1 as described by K. M. Mohler *et al.*, (1994) Nature 370:218-220. The purified enzyme activity and inhibition thereof is determined by incubating the partially
30 purified enzyme in the presence or absence of test compounds using the substrate 4',5'-Dimethoxy-fluoresceinyl Ser.Pro.Leu.Ala.Gln.Ala.Val.Arg.Ser.Ser.Ser.Arg.Cys(4-(3-succinimid-1-yl)-fluorescein)-NH₂ in assay buffer (50mM Tris HCl, pH 7.4 containing 0.1%

-32-

(w/v) Triton X-100 and 2mM CaCl₂), at 26°C for 4 hours. The amount of inhibition is determined as for MMP13 except λ_{ex} 485nm and λ_{em} 538nm were used. The substrate was synthesised as follows. The peptidic part of the substrate was assembled on Fmoc-NH-Rink-MBHA-polystyrene resin either manually or on an automated peptide synthesiser by standard methods involving the use of Fmoc-amino acids and O-benzotriazol-1-yl-N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) as coupling agent with at least a 4- or 5-fold excess of Fmoc-amino acid and HBTU. Ser¹ and Pro² were double-coupled. The following side chain protection strategy was employed; Ser¹(But), Gln⁵(Trityl), Arg^{8,12}(Pmc or Pbf), Ser^{9,10,11}(Trityl), Cys¹³(Trityl). Following assembly, the N-terminal Fmoc-protecting group was removed by treating the Fmoc-peptidyl-resin with in DMF. The amino-peptidyl-resin so obtained was acylated by treatment for 1.5-2 hours at 70°C with 1.5-2 equivalents of 4',5'-dimethoxy-fluorescein-4(5)-carboxylic acid [Khanna & Ullman, (1980) Anal Biochem. 108:156-161) which had been preactivated with diisopropylcarbodiimide and 1-hydroxybenzotriazole in DMF]. The dimethoxyfluoresceinyl-peptide was then simultaneously deprotected and cleaved from the resin by treatment with trifluoroacetic acid containing 5% each of water and triethylsilane. The dimethoxyfluoresceinyl-peptide was isolated by evaporation, trituration with diethyl ether and filtration. The isolated peptide was reacted with 4-(N-maleimido)-fluorescein in DMF containing diisopropylethylamine, the product purified by RP-HPLC and finally isolated by freeze-drying from aqueous acetic acid. The product was characterised by MALDI-TOF MS and amino acid analysis.

The compounds of the invention have been found to be active against TACE at 0.1nM to 50µM, and in particular 10µM of compound 1 gave 72% inhibition, and 10µM of compound 3 gave 72% inhibition.

Natural Substrates

The activity of the compounds of the invention as inhibitors of aggrecan degradation may be assayed using methods for example based on the disclosures of E. C. Arner *et al.*, (1998) Osteoarthritis and Cartilage 6:214-228; (1999) Journal of Biological Chemistry, 274(10), 6594-6601 and the antibodies described therein. The potency of compounds to act as inhibitors against collagenases can be determined as described by T. Cawston and A. Barrett (1979) Anal. Biochem. 99:340-345.

Inhibition of metalloproteinase activity in cell/tissue based activity

Test as an agent to inhibit membrane sheddases such as TNF convertase

The ability of the compounds of this invention to inhibit the cellular processing of TNF α production may be assessed in THP-1 cells using an ELISA to detect released TNF essentially as described K. M. Mohler *et al.*, (1994) Nature 370:218-220. In a similar fashion
5 the processing or shedding of other membrane molecules such as those described in N. M. Hooper *et al.*, (1997) Biochem. J. 321:265-279 may be tested using appropriate cell lines and with suitable antibodies to detect the shed protein.

Test as an agent to inhibit cell based invasion

The ability of the compound of this invention to inhibit the migration of cells in an
10 invasion assay may be determined as described in A. Albini *et al.*, (1987) Cancer Research 47:3239-3245.

Test as an agent to inhibit whole blood TNF sheddase activity

The ability of the compounds of this invention to inhibit TNF α production is assessed in a human whole blood assay where LPS is used to stimulate the release of TNF α . 160 μ l of
15 heparinized (10Units/ml) human blood obtained from volunteers, was added to the plate and incubated with 20 μ l of test compound (duplicates), in RPMI1640 + bicarbonate, penicillin, streptomycin, glutamine and 1% DMSO, for 30 minutes at 37°C in a humidified (5%CO₂/95%air) incubator, prior to addition of 20 μ l LPS (E. coli. 0111:B4; final concentration 10 μ g/ml). Each assay includes controls of neat blood incubated with medium
20 alone or LPS (6 wells/plate of each). The plates are then incubated for 6 hours at 37°C (humidified incubator), centrifuged (2000rpm for 10 min; 4°C), plasma harvested (50-100 μ l) and stored in 96 well plates at -70°C before subsequent analysis for TNF α concentration by ELISA.

Test as an agent to inhibit in vitro cartilage degradation

25 The ability of the compounds of this invention to inhibit the degradation of the aggrecan or collagen components of cartilage can be assessed essentially as described by K. M. Bottomley *et al.*, (1997) Biochem J. 323:483-488.

In vivo assessment**30 Test as an anti-TNF agent**

The ability of the compounds of this invention as *in vivo* TNF α inhibitors is assessed in the rat. Briefly, groups of female Wistar Alderley Park (AP) rats (90-100g) are dosed with

compound (5 rats) or drug vehicle (5 rats) by the appropriate route e.g. peroral (p.o.), intraperitoneal (i.p.), subcutaneous (s.c.) 1 hour prior to lipopolysaccharide (LPS) challenge (30µg/rat i.v.). Sixty minutes following LPS challenge rats are anaesthetised and a terminal blood sample taken via the posterior vena cavae. Blood is allowed to clot at room temperature for 2 hours and serum samples obtained. These are stored at -20°C for TNFα ELISA and compound concentration analysis.

Data analysis by dedicated software calculates for each compound/dose:

$$\text{Percent inhibition of TNF}\alpha = \frac{\text{Mean TNF}\alpha (\text{Vehicle control}) - \text{Mean TNF}\alpha (\text{Treated})}{\text{Mean TNF}\alpha (\text{Vehicle control})} \times 100$$

10 Test as an anti-arthritis agent

Activity of a compound as an anti-arthritis is tested in the collagen-induced arthritis (CIA) as defined by D. E. Trentham *et al.*, (1977) J. Exp. Med. 146:857. In this model acid soluble native type II collagen causes polyarthritis in rats when administered in Freund's incomplete adjuvant. Similar conditions can be used to induce arthritis in mice and primates.

15 Pharmaceutical Compositions

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.

The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. The composition may also be in a form suitable for inhalation.

In general the above compositions may be prepared in a conventional manner using conventional excipients.

The pharmaceutical compositions of this invention will normally be administered to humans so that, for example, a daily dose of 0.5 to 75 mg/kg body weight (and preferably 0.5 to 30 mg/kg body weight) is received. This daily dose may be given in divided doses as necessary, the precise amount of the compound received and the route of administration depending on the weight, age and sex of the patient being treated and on the particular disease

condition being treated according to principles known in the art.

Typically unit dosage forms will contain about 1 mg to 500 mg of a compound of this invention.

Therefore in a further aspect of the present invention there is provided a compound of
5 formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, for use in a method of treatment of a warm-blooded animal such as man by therapy.

Also provided is a compound of formula (1), or a pharmaceutically acceptable salt or
in vivo hydrolysable ester thereof, as defined hereinbefore, for use in a method of treating a
10 disease condition mediated by one or more metalloproteinase enzymes and in particular a disease condition mediated by TNF α .

Further provided is a compound of formula (1), or a pharmaceutically acceptable salt
or *in vivo* hydrolysable ester thereof, as defined hereinbefore, for use in a method of treating
inflammatory diseases, autoimmune diseases, allergic/atopic diseases, transplant rejection,
15 graft versus host disease, cardiovascular disease, reperfusion injury and malignancy in a warm-blooded animal such as man. In particular a compound of formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, is provided for use in a method of treating rheumatoid arthritis, Crohn's disease and psoriasis, and especially rheumatoid arthritis. A compound of formula (1), or a pharmaceutically
20 acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, is provided for use in a method of treating a respiratory disorder such as asthma or COPD.

According to an additional aspect of the invention there is provided a compound of formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, for use as a medicament.

25 Also provided is a compound of formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, for use as a medicament in the treatment of a disease condition mediated by one or more metalloproteinase enzymes and in particular a disease condition mediated by TNF α .

Further provided is a compound of formula (1), or a pharmaceutically acceptable salt
30 or *in vivo* hydrolysable ester thereof, as defined hereinbefore, for use as a medicament in the treatment of inflammatory diseases, autoimmune diseases, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy.

in a warm-blooded animal such as man. In particular a compound of formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, is provided for use as a medicament in the treatment of rheumatoid arthritis, Crohn's disease and psoriasis, and especially rheumatoid arthritis. A compound of formula (1), or a
5 pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, is also provided for use as a medicament in the treatment of a respiratory disorder such as asthma or COPD.

According to another aspect of the invention there is provided the use of a compound of formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as
10 defined hereinbefore in the manufacture of a medicament for use in the treatment of a disease condition mediated by one or more metalloproteinase enzymes and in particular a disease condition mediated by TNF α in a warm-blooded animal such as man.

Also provided is the use of a compound of formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore in the
15 manufacture of a medicament for use in the treatment of inflammatory diseases, autoimmune diseases, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy in a warm-blooded animal such as man. In particular the use of a compound of formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, is provided in the manufacture of a
20 medicament in the treatment of rheumatoid arthritis, Crohn's disease and psoriasis, and especially rheumatoid arthritis. The use of a compound of formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, is also provided in the manufacture of a medicament in the treatment of a respiratory disorder such as asthma or COPD.

25 According to a further feature of this aspect of the invention there is provided a method of producing a metalloproteinase inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1).

According to a further feature of this aspect of the invention there is provided a
30 method of producing a TACE inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1).

According to this further feature of this aspect of the invention there is provided a method of treating autoimmune disease, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy in a warm-blooded animal, such as man, in need of such treatment which comprises administering
5 to said animal an effective amount of a compound of formula (1).

Also provided is a method of treating rheumatoid arthritis, Crohn's disease and psoriasis, and especially rheumatoid arthritis in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1). Further provided is a method of treating a respiratory disorder such
10 as asthma or COPD in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1).

In addition to their use in therapeutic medicine, the compounds of formula (1) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of *in vitro* and *in vivo* test systems for the evaluation of the
15 effects of inhibitors of cell cycle activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.

In the above other pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and preferred embodiments of the compounds of the invention described herein also apply.

20

Examples

The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:

- (i) temperatures are given in degrees Celsius (°C); operations were carried out at room or
25 ambient temperature, that is, at a temperature in the range of 18-25°C;
- (ii) organic solutions were dried over anhydrous magnesium sulphate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 Pascals; 4.5-30 mm Hg) with a bath temperature of up to 60°C;
- (iii) chromatography unless otherwise stated means flash chromatography on silica gel; thin
30 layer chromatography (TLC) was carried out on silica gel plates; where a "Bond Elut" column is referred to, this means a column containing 10g or 20g of silica of 40 micron particle size, the silica being contained in a 60ml disposable syringe and supported by a porous disc,

obtained from Varian, Harbor City, California, USA under the name "Mega Bond Elut SI".

Where an "IsoluteTM SCX column" is referred to, this means a column containing benzenesulphonic acid (non-endcapped) obtained from International Sorbent Technology Ltd., 1st House, Duffryn Industrial Estate, Ystrad Mynach, Hengoed, Mid Glamorgan, UK. Where

5 Flashmaster II is referred to, this means a UV driven automated chromatography unit supplied by Jones;

(iv) in general, the course of reactions was followed by TLC and reaction times are given for illustration only;

(v) yields, when given, are for illustration only and are not necessarily those which can be
10 obtained by diligent process development; preparations were repeated if more material was required;

(vi) when given, ¹H NMR data is quoted and is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz using perdeuterio DMSO (CD₃SOCD₃) as the
15 solvent unless otherwise stated; coupling constants (J) are given in Hz;

(vii) chemical symbols have their usual meanings; SI units and symbols are used;

(viii) solvent ratios are given in percentage by volume;

(ix) mass spectra (MS) were run with an electron energy of 70 electron volts in the chemical ionisation (APCI) mode using a direct exposure probe; where indicated ionisation was
20 effected by electrospray (ES); where values for m/z are given, generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion - (M+H)⁺;

(x) LCMS characterisation was performed using a pair of Gilson 306 pumps with Gilson 233 XL sampler and Waters ZMD4000 mass spectrometer. The LC comprised water symmetry
25 4.6x50 column C18 with 5 micron particle size. The eluents were: A, water with 0.05% formic acid and B, acetonitrile with 0.05% formic acid. The eluent gradient went from 95% A to 95% B in 6 minutes. Where indicated ionisation was effected by electrospray (ES); where values for m/z are given, generally only ions which indicate the parent mass are reported, and, unless otherwise stated the mass ion quoted is the positive mass ion - (M+H)⁺ and

30 (xi) the following abbreviations are used:


DMSO dimethyl sulphoxide;

DMF N-dimethylformamide;

DCM	dichloromethane;
NMP	<i>N</i> -methylpyrrolidinone;
DIAD	Di- <i>isopropyl</i> azodicarboxylate
LHMDS or LiHMDS	Lithium bis(trimethylsilyl)amide
5 MeOH	Methanol
RT	Room temperature
TFA	Trifluoroacetic acid
EtOH	ethanol
EtOAc	ethyl acetate.
10 EDTA	ethylenediaminetetraacetic acid
THF	tetrahydrofuran
TBDMS	tertiarybutyldimethylsilyl
DIPEA	diisopropylethylamine
MTBE	methyltertiarybutylether

EXAMPLE 1

(R/S)-1-([4-(But-2-ynoxy)piperidin-1-yl]sulphonyl)methyl)-4-pyrimidin-2-ylbutyl(hydroxy)formamide



20 To a stirred solution of (R/S)-[1-([4-(4-but-2-ynoxy)piperidin-1-yl]sulphonyl)methyl)-4-pyrimidin-2-ylbutyl]hydroxylamine (170mg, 0.43mmol) in THF (5.0ml), was added a preformed mixture of acetic anhydride (200μl, 2.1mmol) and formic acid (0.75ml). The mixture was stirred at RT for 23 hours. The solvents were removed by rotary evaporation, EtOAc (15ml) followed by saturated sodium hydrogen carbonate was added and the reaction
25 mixture was stirred for 4 hours. The mixture was diluted with EtOAc (15ml) and washed with brine (10ml), dried (Na₂SO₄) and evaporated to give a colourless film. The aqueous layer was re-extracted with DCM (3x10ml), dried (Na₂SO₄) and combined with the previous product. This residue was purified by chromatography (Flashmaster II, eluent 0→10% MeOH/DCM) to give a mixture. The mixture was redissolved in MeOH (5ml) and K₂CO₃ was

added. After 16h the solution was concentrated, partitioned between DCM and brine, the organic layer was dried (Na_2CO_3) and concentrated to give the title compound as a pure oil (84mg, 46%). NMR(CDCl_3): 8.69 (d, 2H), 8.22 & 7.90 (br s, 1H), 7.3 (t, 1H), 4.1 (q, 2H), 3.58 (m, 1H), 3.3 (m, 4H), 3.02 (m, 2H), 2.83 (m, 2H), and 1.8-1.47 (m, 11H); MS: 425.

5

The starting material (R/S)-[1-([4-(4-but-2-ynyloxy)piperidin-1-yl]sulphonyl)methyl]-4-pyrimidin-2-ylbutyl]hydroxylamine was prepared as follows :

- i) To solution of 4-hydroxypiperidine (20g, 198mmol) in 2M aqueous sodium hydroxide (350ml) was added methanesulphonyl chloride (25ml, 323mmol) over 10 minutes. The solution was stirred at ambient temperature for a further 1 hour. The reaction mixture was poured into EtOAc (300ml) and the organic phase separated. The aqueous phase was extracted with EtOAc (2 x 300ml). The combined organic phases were dried (Na_2SO_4) and filtered. The filtrate was treated with SCX-2 resin (20g) for 15 minutes before filtration and evaporation to give 4-hydroxy-1-(methanesulphonyl)piperidine as a white solid, (6.62g, 19%).
10 NMR(CDCl_3): 3.95 (m, 1H), 3.45 (m, 2H), 3.10 (m, 2H), 2.75 (s, 3H), 1.95 (m, 2H), 1.70 (m, 2H).
- ii) To a suspension of sodium hydride (60% dispersion, 1.5g, 37.5mmol) in DMF (350ml) was added a solution of 4-hydroxy-1-(methanesulphonyl)piperidine (6.4g, 35.7mmol) in DMF (50ml). After 20 minutes at RT, 1-bromobut-2-yne (3.0ml, 34.3mmol) was added rapidly. After 4 hours, at RT water (5ml) was added and the mixture left to stand for 16 hours. The solvent was concentrated and the resultant brown oil was partitioned between brine (200ml) and EtOAc (200ml). The aqueous phase was extracted with EtOAc (2x200ml) and the organic layers combined. The combined extracts were dried (Na_2SO_4) and concentrated to give a brown oil which was purified by chromatography (Flashmaster II, 70g silica column, eluted with 0→100% EtOAc / *iso*-Hexane gradient) to give 4-(but-2-ynyloxy)-1-methanesulphonylpiperidine (1.8g, 22% Yield). NMR(CDCl_3): 4.14 (q, 2H), 3.75 (m, 1H), 3.35 (m, 2H), 3.21 (m, 2H), 2.77 (s, 3H), 1.90 (m, 2H), 1.85 (t, 3H), 1.82 (m, 2H).
20
- iii) To a stirred solution of the 4-(but-2-ynyloxy)-1-methanesulphonylpiperidine (461mg, 2mmol) in THF (15ml) at -15°C was added LiHMDS (4.4ml, 1.0M solution in THF, 4.4mmol). The solution was then stirred at this temperature for 30 minutes. A solution of ethyl 4-(pyrimidin-2-yl)butanoate§ (400 mg, 2.1 mmol) in THF (1 ml) was then added dropwise. The reaction was slowly allowed to warm to 5°C , then after 20 minutes, water
30

(2ml) was added. The solution was partitioned between brine (20ml) and EtOAc (10ml), then the aqueous layer was re-extracted with EtOAc (10ml). The combined organic extracts were dried, (Na_2SO_4), filtered and concentrated in vacuo. Flash chromatography (silica gel, 50% EtOAc in hexane) gave 1-{{[4-(but-2-ynyloxy)piperidinyl]sulphonyl}-5-(pyrimidin-2-

5 yl)pentan-2-one as a yellow oil (286 mg, 38%). NMR(CDCl_3): 8.67 (d, 2H), 7.13 (t, 1H), 4.13 (q, 2H), 3.96 (s, 2H), 3.72 (m, 1H), 3.47 (m, 2H), 3.22 (m, 2H), 3.0 (t, 2H), 2.84 (t, 2H), 2.16 (m, 2H), 1.98 (m, 2H), 1.85 (t, 3H), 1.76 (m, 2H); MS: 380.

iv) To a stirred solution of 1-{{[4-(but-2-ynyloxy)piperidinyl]sulphonyl}-5-(pyrimidin-2-yl)pentan-2-one (286mg, 0.75mmol) in EtOH (5ml) was added sodium borohydride (15mg) and the mixture stirred at RT. After 25 minutes the reaction mixture was concentrated and EtOAc (20ml) was added. The organic layer was washed with brine (20ml) and the aqueous fraction re-extracted with EtOAc (20ml). The combined organics were dried (Na_2SO_4) and evaporated to give (R/S)-1-{{[4-(but-2-ynyloxy)piperidinyl]sulphonyl}-5-(pyrimidin-2-yl)pentan-2-ol (286mg, 100% yield). NMR: 8.67 (d, 2H), 7.14 (t, 1H), 4.24 (m, 1H), 4.13 (q, 15 2H), 3.74 (m, 1H), 3.56 (br s, 1H), 3.42 (m, 2H), 3.24 (m, 2H), 3.02 (m, 4H), 1.85 (t, 3H), 1.81 (m, 8H); MS: 382.


v) To a stirred solution of (R/S)-1-{{[4-(but-2-ynyloxy)piperidinyl]sulphonyl}-5-(pyrimidin-2-yl)pentan-2-ol (286mg, 0.75mmol) in DCM (5ml) was added triethylamine (260 μl , 1.9mmol) followed by methanesulphonyl chloride (65 μl , 0.83mmol) and the mixture 20 stirred at RT. After 21 hours the reaction mixture was poured into brine, diluted with DCM (20ml) and partitioned. The organic layer was dried (Na_2SO_4), evaporated and purified by chromatography (Flashmaster II, 10g silica column, 0 \rightarrow 100% hexane to EtOAc) to give E-1-{{[4-(but-2-ynyloxy)piperidinyl]sulphonyl}-5-(pyrimidin-2-yl)pent-1-ene (158mg, 58% yield). NMR: 8.68 (d, 2H), 7.15 (t, 1H), 6.76 (dt, 1H), 6.12 (d, 1H), 4.12 (q, 2H), 3.68 (m, 1H), 3.30 25 (m, 2H), 3.05 (m, 4H), 2.35 (m, 2H), 2.04 (m, 2H), 1.89 (m, 2H), 1.84 (t, 3H), 1.76 (m, 2H); MS: 364.

vi) To a stirred solution of the E-1-{{[4-(but-2-ynyloxy)piperidinyl]sulphonyl}-5-(pyrimidin-2-yl)pent-1-ene (158mg, 0.43mmol) in THF (5ml) under argon was added hydroxylamine (50% solution in water, 450 μl) and the mixture stirred overnight. The mixture 30 was poured into water (5ml) and EtOAc (15ml) and the partitioned organic layer was washed with brine (5ml), dried (Na_2SO_4) and concentrated to give (R/S)-1-{{[4-(4-but-2-

ynyloxy)piperidin-1-yl]sulphonyl)methyl)-4-pyrimidin-2-ylbutyl]hydroxylamine (170mg, 100%), this was used immediately in the final step.

§Ethyl 4-(pyrimidin-2-yl)butanoate was prepared as follows:

5 Ethyl 4-(pyrimidin-2-yl)butanoate




2-Bromopyrimidine (80g, 500mmol) was slurried in THF (400ml). An inert atmosphere was created by displacing the air atmosphere with nitrogen, followed by degassing the slurry by nitrogen purging. Bis(acetonitrile)palladium (II) chloride (2.5mmol) and triphenylphosphine
 10 (7.5mmol) were charged, followed by 4-ethoxy-4-oxo-butylzinc bromide (0.5M in THF, approximately 600mmol) in 9 portions. The mixture was stirred until the reaction was complete at which point water was added and the solution rotary evaporated to an oil. DCM was added and this solution was washed with 1M EDTA tetrasodium salt, water and brine. The DCM solution was then rotary evaporated to an oil, causing the precipitation of an
 15 impurity. This mixture was dissolved in THF, filtered to remove the impurity, then the solvent removed on a rotary evaporator affording the desired ethyl 4-(pyrimidin-2-yl)butanoate as an orange oil (95.4g, 492mmol). ¹H NMR (400MHz): δ 8.73-8.72 (d, 2H), 7.35-7.33 (t, 1H), 4.07-4.02 (q, 2H), 2.91-2.88 (t, 2H), 2.38-2.34 (t, 2H), 2.05-1.97 (m, 2H), 1.20-1.16 (t, 3H)

20

EXAMPLE 2

(R/S)-1-[(4-[(but-2-ynyloxy)methyl]piperidin-1-yl)sulphonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide



25 The procedure described in Example 1 was followed except that 4-(but-2-ynyloxymethyl)-1-(methanesulphonyl)piperidine (360mg, 1.47mmol) was used (synthesis described below) in

-43-


place of 4-(but-2-ynyloxy)-1-methanesulphonylpiperidine to give (R/S)-1-[(4-[(but-2-ynyloxy)methyl]piperidin-1-yl)sulphonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide (169mg, 0.38mmol). NMR: 8.68 (d, 2H), 8.48 (s, 0.5H), 8.04 (d, 0.5H), 7.23 (t, 0.5H), 7.19 (t, 0.5H), 4.08 (m, 2H), 3.78 (m, 2H), 3.3 (m, 4H), 3.06 (m, 4H), 2.78 (m, 2H), 1.92 (m, 2H),
5 1.85 (t, 3H), 1.7 (m, 7H) ; MS: 439

The starting 4-(but-2-ynyloxymethyl)-1-(methanesulphonyl)piperidine was prepared as follows:

- i) To a stirred solution of piperidin-4-ylmethanol (2g, 17.4mmol) dissolved in DCM
10 (250ml) was added triethylamine (6ml, 43.5mmol) followed by methanesulphonyl chloride (3.0ml, 38.2mmol). After 2.5 hours at RT the reaction mixture was diluted with EtOAc (500ml) and the organic layer washed with 2M HCl (100ml), NaHCO₃ (100ml), brine (100ml), dried (Na₂SO₄) and evaporated to give 4-(methanesulphonyloxymethyl)-1-methanesulphonylpiperidine as an off-white solid (4.5g, 96%). NMR(CDCl₃): 4.1 (d, 2H),
15 3.86 (m, 2H), 3.02 (s, 3H), 2.79 (s, 3H), 2.67 (m, 2H), 1.89 (m, 3H), 1.43 (m, 2H).
- ii) To a stirred solution of but-2-yn-1-ol (550ul, 7.4mmol) in DMF (25ml) was added sodium hydride (300mg, 8.1mmol). After 90 minutes a solution of 4-(methanesulphonyloxymethyl)-1-methanesulphonylpiperidine (2.0g, 7.4mmol) in DMF (30ml) was added. After 2 hours stirring at RT water (5ml) was added and the mixture
20 concentrated to a brown oil. This was partitioned between EtOAc (100ml) and brine (150ml). The aqueous layers were re-extracted with EtOAc (2x50ml) and the combined organic fractions were dried (Na₂SO₄), evaporated and purified by chromatography (Flashmaster II, 50g silica, 50→100% hexane to EtOAc) to give 4-(but-2-ynyloxymethyl)-1-(methanesulphonyl)piperidine (680mg, 2.8mmol, 37%). NMR(CDCl₃): 4.07 (q, 2H), 3.81 (br
25 m, 2H), 3.35 (d, 2H), 2.76 (s, 3H), 2.64 (m, 2H), 1.8 (m, 5H), 1.71 (m, 1H), 1.35 (m, 2H).

EXAMPLE 3

(R/S)-2-({4-[(But-2-ynyloxy)methyl]piperidin-1-yl}sulphonyl)-1-methylethyl(hydroxy)formamide



To a stirred solution of (R/S)-2-{{4-(but-2-ynyloxymethyl)piperidin-1-yl}sulphonyl}-1-methylethylhydroxylamine (112mg, 0.37mmol) in THF (5.0ml), was added a preformed mixture of acetic anhydride (200µl, 2.1mmol) and formic acid (0.75ml). The mixture was stirred at RT overnight. The solvents were removed by rotary evaporation, EtOAc (10ml) followed by saturated sodium hydrogen carbonate and the reaction mixture was stirred for 2 hours. The mixture was washed with brine (10ml), dried (Na₂SO₄) and evaporated to give a pale yellow oil. This residue was purified by chromatography (Flashmaster II, eluent 0→60% EtOAc / DCM) to give (R/S)-2-({4-[(but-2-ynyloxy)methyl]piperidin-1-yl}sulphonyl)-1-methylethyl(hydroxy)formamide (75mg, 0.22mmol). NMR(CDCl₃): 7.96 (s, 1H), 4.36 (m, 1H), 4.08 (q, 2H), 3.77 (m, 2H), 3.47 (dd, 1H), 3.34 (d, 2H), 2.90 (dd, 2H), 2.75 (m, 2H), 1.85 (t, 3H), 1.82 (m, 2H), 1.74 (m, 1H), 1.48 (d, 3H), 1.34 (m, 2H); MS: 333.

The starting material (R/S)-2-{{4-(but-2-ynyloxymethyl)piperidin-1-yl}sulphonyl}-1-methylethylhydroxylamine was prepared as follows:

i) To a stirred solution of the 4-(but-2-ynyloxymethyl)-1-methanesulphonylpiperidine (prepared above) (320mg, 1.3mmol) in THF (10ml) at -17°C under argon was added LiHMDS (2.8ml, 1.0M solution in THF, 2.8mmol). The solution was then stirred at this temperature for 30 minutes. A solution of diethylchlorophosphate (190µl, 1.31mmol) was then added and the reaction mixture stirred at 0°C for a further 50 minutes. Acetaldehyde (100µL, 1.8mmol) was then added. After 15 hours the reaction was quenched with saturated ammonium chloride (10ml). The organic phase was separated and the aqueous layer extracted with EtOAc (30ml). The combined organics were combined, washed with brine (10ml), dried (Na₂SO₄), concentrated and chromatographed (Flashmaster II, 50g silica, 50→100% hexane to EtOAc) to give E/Z-{1-[4-(4-but-2-ynyloxymethyl)piperidin-1-yl]sulphonyl}prop-1-ene as a yellow oil (100 mg, 0.37mmol). MS: 272.

ii) To a stirred solution of the E/Z-{1-[4-(4-but-2-ynyloxymethyl)piperidin-1-yl]sulphonyl}prop-1-ene (100mg, 0.37mmol) in THF (5ml) under argon was added hydroxylamine (50% solution in water, 450µl) and the mixture stirred over the weekend. The


-45-

mixture was poured into water (5ml) and EtOAc (15ml) and the partitioned organic layer was washed with brine (5ml), dried (Na_2SO_4) and concentrated to give (R/S)-2-{[4-(but-2-ynyloxymethyl)piperidin-1-yl]sulphonyl}-1-methylethylhydroxylamine (112mg, 0.37mmol). This was used immediately in the final step.

5

EXAMPLE 4

2-(4-But-2-ynyloxymethylpiperidin-1-ylsulphonylmethyl)-4-methyl-pentanoic acid hydroxyamide



- 10 To a stirred solution of 2-(4-but-2-ynyloxymethylpiperidin-1-ylsulphonylmethyl)-4-methylpentanoic acid (350mg, 0.97mmol) in DCM (20ml) was added DMF (2 drops) and oxalyl chloride (0.1ml, 1.16mmol). The reaction was stirred for 1 hour at RT and then evaporated to dryness at RT to give a yellow solid. The solid was redissolved in DCM (6ml) and added dropwise, over 5 minutes, to a solution of hydroxylamine (50% aq., 1.0ml) in THF
- 15 (15ml). The resultant solution was stirred at RT for 1 hour and then evaporated under reduced pressure. The crude product was purified by chromatography (Flashmaster II, 20g silica bond elute, eluent 50% to 80% EtOAc / isohexane) to give the product, as a white solid (160mg, 0.43mmol). NMR (400MHz, CDCl_3) 0.91 (d, 3H), 0.93 (d, 3H), 1.34 (m, 2H), 1.71 (m, 2H), 1.81 (m, 1H), 1.85 (t, 3H), 2.71 (m, 2H), 2.83 (dd, 1H), 3.35 (d, 2H), 3.42 (dd, 1H), 3.72 (m,
- 20 2H), 4.08 (q, 2H); MS: 375.

The starting material 2-(4-but-2-ynyloxymethylpiperidin-1-ylsulphonylmethyl)-4-methyl-pentanoic acid was prepared as follows :


- i) To a solution of 4-but-2-ynyloxymethyl-1-methanesulphonylpiperidine (520mg, 2.12mmol) in THF (7ml) cooled to -16°C was added LiHMDS (1.0M in THF, 2.2ml, 2.2mmol). The solution was stirred at -16°C for 10 minutes. To this solution was added a solution of 3-isobutyl-oxiran-2-one in THF, dropwise, at -16°C , (prepared by addition of LiHMDS (1.0M in THF, 2.3ml, 2.3mmol) to a solution of 2-bromoisocaproic acid (431mg, 2.2mmol) in THF (7ml) at -16°C). Stirring was continued at RT for 1 hours. The reaction
- 25

-46-

was quenched with ammonium chloride solution (saturated aqueous, 5ml). 2M HCl (8ml) and EtOAc (20ml) were added. The organic phase was separated. The aqueous phase extracted with EtOAc (20ml). The combined organic phases were washed with brine (20ml), dried (Na_2SO_4), evaporated and purified by chromatography (Flashmaster II, 50g, eluent 50 \rightarrow 80% EtOAc / isohexane) to give 2-(4-but-2-ynyloxymethylpiperidin-1-ylsulphonylmethyl)-4-methyl-pentanoic acid (350mg, 0.97mmol) as a yellow oil. NMR (400MHz, CDCl_3) 0.94(d, 3H), 0.97 (d, 3H), 1.30-1.74 (8H, m), 1.85 (t, 3H), 2.65 (td, 1H), 2.75 (m, 1H), 2.90 (dd, 1H), 3.02 (m, 1H), 3.45 (d, 1H), 3.78 (m, 2H), 4.08 (m, 2H); MS 360.

10 EXAMPLE 5

(R/S)-2-({4-[Prop-2-enyloxy]piperidin-1-yl}sulphonyl)-1-phenylethyl(hydroxy)formamide



To a solution of (R/S)-2-{{4-[prop-2-enyloxy]piperidin-1-yl}sulphonyl}-1-phenylethylhydroxylamine (described below) (0.75mmol) in DCM (1ml) was added a pre-mixture of formic acid (2ml) and acetic anhydride (1ml) and stirred at RT overnight. Methanol (5ml) was then added and, after stirring for 30 minutes, the mixture was evaporated. The residue was re-dissolved in methanol (2ml) and allowed to stand at RT overnight. After evaporation, the mixture was purified by BondElut chromatography (10g Silica), eluting with a gradient from DCM to 5% methanol in DCM to give (R/S)-2-[prop-2-enyloxy]piperidin-1-yl}sulphonyl)-1-phenylethyl(hydroxy)formamide (0.16mmol, 0.059g) as a solid. MS: 369.

The starting (R/S)-2-{{4-[prop-2-enyloxy]piperidin-1-yl}sulphonyl}-1-phenylethylhydroxylamine was prepared as follows:

i) Triethylamine (8.0g, 0.079mol) was added to a stirred solution of *E*- β -styrenesulphonyl chloride (12.0g, 0.059mol) and 4-hydroxypiperidine (8.0g, 0.079mol) in THF (100ml) at RT. Stirring was continued overnight before the reaction mixture was reduced to low volume and partitioned between EtOAc followed by aqueous 1M HCl, saturated NaHCO_3 and brine. The organic fraction was then dried (Na_2SO_4) and evaporated to give *E*-[4-hydroxypiperidin-1-ylsulphonyl]-2-phenylethene. (12.75g; 0.046mol); NMR


-47-


(CDCl₃): 1.5–1.8 (m, 4H), 1.9–2.1 (m, 2H), 3.0–3.2 (m, 2H), 3.4–3.6 (m, 2H), 3.85 (s, 1H), 6.65 (s, 1H), 7.3–7.6 (m, 6H); MS: 268.

- ii) E-[4-hydroxypiperidin-1-ylsulphonyl]-2-phenylethene (0.2g, 0.75mmol) was dissolved in DMF (3ml) and added to allyl bromide (1.5mmol). A covering of argon gas was introduced to the tube before solid sodium hydride (0.1g; incl. oil) was carefully added, in three portions to the stirred reaction. Stirring was continued overnight. Water (5ml) was added (dropwise initially) and the resultant mixture extracted with EtOAc (5ml). The organic layer was separated and the aqueous layer washed again with EtOAc (3ml). The combined organics were evaporated, re-dissolved in DCM (5ml) and applied to a 10g Silica BondElut column and eluted with a gradient from DCM to 2.5% MeOH in DCM to give E-[4-[prop-2-enyloxy]piperidin-1-ylsulphonyl]-2-phenylethene which was carried through to the next step.
- iii) E-[4-[prop-2-enyloxy]piperidin-1-ylsulphonyl]-2-phenylethene was dissolved in THF (1ml) and the air in the tubes excluded with argon before hydroxylamine in water (50% solution, 1ml) was added and the mixture stirred vigorously overnight. EtOAc (1ml) was added and the aqueous layer separated. The organic layers were washed with brine and dried (Na₂SO₄) and concentrated to give (R/S)-2-[[4-[prop-2-enyloxy]piperidin-1-yl]sulphonyl]-1-phenylethylhydroxylamine which was carried through to the final step.

EXAMPLES 6 and 7

- The method described in Example 5 was followed except allyl bromide was replaced with the appropriate halide to give the products shown below.


Example Number	Structure and Name	Starting phenol	MH+
6	 <p>(R/S)-2-((4-[but-2-enyloxy]piperidin-1-yl)sulphonyl)-1-phenylethyl(hydroxy)formamide</p>	1-bromo-but-2-ene	383

7	 <p data-bbox="370 489 850 638">(R/S)-2-({4-[3-phenyl-prop-2-enyloxy]piperidin-1-yl}sulphonyl)-1-phenylethyl(hydroxy)formamide</p>	1-bromo, 3-phenyl-prop-2-ene	439
---	---	------------------------------	-----

CLAIMS:

What we claim is :-

1. A compound of formula (1):



formula (1)

wherein Z is selected from $-\text{CONR}^{15}\text{OH}$ and $-\text{N}(\text{OH})\text{CHO}$;

R^{15} is hydrogen or C_{1-3} alkyl;

wherein R^1 is hydrogen or a group selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{5-7} cycloalkenyl, aryl, heteroaryl and heterocyclyl where the group is optionally

- 10 substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-6} cycloalkyl (optionally substituted by one or more R^{17}), aryl (optionally substituted by one or more R^{17}), heteroaryl (optionally substituted by one or more R^{17}), heterocyclyl, C_{1-4} alkoxycarbonyl, $-\text{OR}^5$, $-\text{SR}^2$, $-\text{SOR}^2$, $-\text{SO}_2\text{R}^2$, $-\text{COR}^2$, $-\text{CO}_2\text{R}^5$, $-\text{CONR}^5\text{R}^6$, $-\text{NR}^{16}\text{COR}^5$, $-\text{SO}_2\text{NR}^5\text{R}^6$ and $-\text{NR}^{16}\text{SO}_2\text{R}^2$;

R^{16} is hydrogen or C_{1-3} alkyl;

R^{17} is selected from halo, C_{1-6} alkyl, C_{3-6} cycloalkyl and C_{1-6} alkoxy;

R^2 is group selected from C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{5-7} cycloalkenyl, heterocycloalkyl, aryl, heteroaryl, aryl C_{1-4} alkyl and heteroaryl C_{1-4} alkyl where the group is optionally substituted by

- 20 one or more halo;

R^5 is hydrogen or a group selected from C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{5-7} cycloalkenyl, heterocycloalkyl, aryl, heteroaryl, aryl C_{1-4} alkyl and heteroaryl C_{1-4} alkyl where the group is optionally substituted by one or more halo;

R^6 is hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl;

- 25 or R^5 and R^6 together with the nitrogen to which they are attached form a heterocyclic 4- to 7-membered ring;

wherein R^8 is hydrogen or a group selected from C_{1-6} alkyl, C_{3-7} cycloalkyl and heterocyclyl where the group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy and C_{1-4} alkyl;

-50-

or R^1 and R^8 together form a carbocyclic or saturated heterocyclic 3- to 6-membered ring;
 wherein R^3 and R^4 are independently hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{5-7} cycloalkenyl,
 heterocyclyl, aryl or heteroaryl;

wherein n is 0 or 1;

5 wherein m is 0 or 1;

wherein D is hydrogen, C_{1-4} alkyl, C_{3-6} cycloalkyl or fluoro;

wherein X is $-(CR^9R^{10})-Q-(CR^{11}R^{12})_u-$ where u is 0 or 1;

Q is O, S, SO or SO_2 ;

R^9 , R^{10} , R^{11} and R^{12} are independently selected from hydrogen, C_{1-4} alkyl and C_{3-6} cycloalkyl;

10 wherein B is C_{2-4} alkenyl or C_{2-4} alkynyl, each being optionally independently substituted by a
 group selected from C_{1-4} alkyl, C_{3-6} cycloalkyl, heterocycloalkyl, aryl, heteroaryl, heterocyclyl
 whereby the group is optionally substituted by one or more halo, nitro, cyano, trifluoromethyl,
 trifluoromethoxy, $-\text{CONHR}^{13}$, $-\text{CONHR}^{13}R^{14}$, $-\text{SO}_2R^{13}$, $-\text{SO}_2\text{NHR}^{13}$, $-\text{SO}_2\text{NR}^{13}R^{14}$, $-\text{NHSO}_2R^{13}$, C_{1-4} alkyl and C_{1-4} alkoxy;

15 R^{13} and R^{14} are independently hydrogen, C_{1-4} alkyl or C_{3-5} cycloalkyl;

or R^{13} and R^{14} together with the nitrogen to which they are attached form a heterocyclic 4 to
 7-membered ring.

or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.

20 2. A compound according to claim 1 wherein X is $-(CH_2)-O-$ or $-(CH_2)-O-(CH_2)-$.

3. A compound according to claim 1 or 2 wherein B is C_{2-4} alkenyl or C_{2-4} alkynyl, each
 being optionally independently substituted by C_{1-4} alkyl, C_{3-6} cycloalkyl, aryl, heteroaryl or
 heterocycloalkyl.

25

4. A compound according to any one of claims 1 to 3 wherein R^1 is hydrogen, C_{1-6} alkyl
 or aryl where C_{1-6} alkyl or aryl are optionally substituted by one or more substituents
 independently selected from C_{1-4} alkyl, aryl (optionally substituted by R^{17}) and heteroaryl
 (optionally substituted by R^{17}) and wherein R^{17} is halo or C_{1-4} alkyl.

5. A compound according to any one of claims 1 to 4 for use as a medicament.

6. The use of a compound according to any one of claims 1 to 4 in the manufacture of a
5 medicament in the treatment of a disease condition mediated by one or more metalloproteinase enzymes.

7. The use of a compound according to any one of claims 1 to 4 in the manufacture of a medicament in the treatment of a disease condition mediated $\text{TNF}\alpha$.

10


8. A method of treating autoimmune disease, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound according to claim 1.

15

9. A pharmaceutical composition comprising a compound according to any one of claims 1 to 4; and a pharmaceutically-acceptable diluent or carrier.

10. A process for preparing a compound according to claim 1 comprising, when Z is –
20 N(OH)CHO , the step of:


a) converting a hydroxylamine of formula (2) into a compound of formula (1);



or when Z is $-\text{CONR}^{15}\text{OH}$, the step of:

25 b) converting an acid of formula (14) into a compound of formula (1);


-52-




and thereafter if necessary:

- i) converting a compound of formula (1) into another compound of formula (1);
- ii) removing any protecting groups;
- 5 iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

11. Ethyl 4-(pyrimidin-2-yl)butanoate.



- 10 12. A process comprising the reaction of a 2-halopyrimidine, 2-tosylpyrimidine, 2-pyrimidinyl triflate or 2-pyrimidinyl mesylate with 4-ethoxy-4-oxo-butylzinc bromide or 4-ethoxy-4-oxo-butylzinc iodide in the presence of a catalyst;



wherein X is halo, triflate or mesylate and Y is bromide or iodide.

15

13. A process according to claim 11 wherein the catalyst is generated from bis(acetonitrile) palladium (II) dichloride and triphenylphosphine.

14. The use of bis(acetonitrile) palladium (II) dichloride and triphenylphosphine in a
20 Negishi coupling reaction.

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number
WO 2004/006927 A3

(51) International Patent Classification⁷: A61K 31/445,
A61P 37/00, C07D 401/12, 239/26, 211/96

R & D Alderley, Alderley Park, Macclesfield, Cheshire
SK10 4TG (GB). PATEL, Ian [GB/GB]; Avlon Works,
Severn Road, Hallen, Bristol, Avon BS10 7ZE (GB).

(21) International Application Number:

PCT/GB2003/002985

(74) Agent: ASTRAZENECA; Global Intellectual Property,
Mereside, Alderley Park, Macclesfield, Cheshire SK10
4TG (GB).

(22) International Filing Date: 9 July 2003 (09.07.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0216382.2

13 July 2002 (13.07.2002) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE,
BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE,
DK, DM, DZ, EC, EE, ES, FI, FR, GB, GD, GE, GH, GM,
GR, HR, HU, ID, IE, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MK, MN, MW, MX,
MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, SY, SZ, TJ, TM, TN, TR, TT, TZ, UA, UG,
UZ, VC, VN, YU, ZA, ZM, ZW only*): ASTRAZENECA
AB [SE/SE]; Sodertalje, S-151 85 (SE).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for MG only*): ASTRAZENECA UK LIM-
ITED [GB/GB]; 15 Stanhope Gate, London, Greater Lon-
don W1K 1LN (GB).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): BURROWS,
Jeremy, Nicholas [GB/GB]; AstraZeneca R & D Alderley,
Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).
TUCKER, Howard [GB/GB]; AstraZeneca R & D Alder-
ley, Alderley Park, Macclesfield, Cheshire SK10 4TG
(GB). BROWN, Simon, James [GB/GB]; AstraZeneca

(88) Date of publication of the international search report:
25 March 2004

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: SULPHONYLPYPERIDINE DERIVATIVES CONTAINING AN ALKENYL OR ALKYNLY MOIETY FOR USE AS
MATRIX METALLOPROTEINASE INHIBITORS

(57) Abstract: A compound of formula
(1): wherein B is optionally substituted
C₂₋₄alkenyl or C₂₋₄alkynyl; useful in the
inhibition of one or more metalloproteinases
and in particular TACE.



A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/445 A61P37/00 C07D401/12 C07D239/26 C07D211/96

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00/46221 A (CARROLL JEFFERY N ;CRESCENZO GARY A DE (US); MISCHKE DEBORAH A (US) 10 August 2000 (2000-08-10) claim 4	1-10
Y	WO 99/24399 A (DARWIN DISCOVERY LTD) 20 May 1999 (1999-05-20) claim 1	1-10
A	WO 00/12478 A (ZENECA PHARMA SA ;TUCKER HOWARD (GB); WATERSON DAVID (GB); ZENECA) 9 March 2000 (2000-03-09) cited in the application claim 1	1-10

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

8 October 2003

Date of mailing of the international search report

02.02.04

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Johnson, C

INTERNATIONAL SEARCH REPORT

In international application No.
PCT/GB 03/02985

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 8 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-10

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No

P IB 03/02985

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0046221	A	10-08-2000	
		AU 2757400 A	25-08-2000
		BG 105788 A	28-02-2002
		BR 0008440 A	26-03-2002
		CA 2362230 A1	10-08-2000
		CN 1362954 T	07-08-2002
		CZ 20012849 A3	15-05-2002
		EE 200100410 A	16-12-2002
		EP 1157021 A1	28-11-2001
		HU 0200119 A2	29-06-2002
		JP 2002536373 T	29-10-2002
		NO 20013850 A	19-09-2001
		PL 350193 A1	18-11-2002
		SK 11352001 A3	10-09-2002
		WO 0046221 A1	10-08-2000
		US 6492367 B1	10-12-2002
		US 6448250 B1	10-09-2002
		US 6372758 B1	16-04-2002
		ZA 200106492 A	07-05-2003
WO 9924399	A	20-05-1999	
		AT 231837 T	15-02-2003
		AU 748843 B2	13-06-2002
		AU 1046999 A	31-05-1999
		BR 9814147 A	03-10-2000
		CA 2308359 A1	20-05-1999
		CN 1283183 T	07-02-2001
		DE 69811111 D1	06-03-2003
		DE 69811111 T2	24-07-2003
		DK 1030836 T3	26-05-2003
		EP 1030836 A1	30-08-2000
		ES 2190115 T3	16-07-2003
		WO 9924399 A1	20-05-1999
		HU 0100152 A2	28-02-2002
		JP 2001522832 T	20-11-2001
		NO 20002440 A	11-05-2000
		NZ 504387 A	25-10-2002
		PL 340551 A1	12-02-2001
		RU 2210567 C2	20-08-2003
		US 6187924 B1	13-02-2001
		ZA 9810360 A	12-11-1999
WO 0012478	A	09-03-2000	
		AU 764367 B2	14-08-2003
		AU 5524799 A	21-03-2000
		BG 105369 A	31-12-2001
		BR 9913255 A	22-05-2001
		CA 2339761 A1	09-03-2000
		CN 1324347 T	28-11-2001
		EE 200100106 A	17-06-2002
		EP 1109787 A1	27-06-2001
		WO 0012478 A1	09-03-2000
		HU 0103344 A2	28-02-2002
		ID 28786 A	05-07-2001
		JP 2002523493 T	30-07-2002
		NO 20011023 A	25-04-2001
		NZ 509730 A	30-05-2003
		PL 346344 A1	11-02-2002
		SK 2702001 A3	06-08-2001
		TR 200100605 T2	21-08-2001
		ZA 200101231 A	13-05-2002

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-10

Compounds of formula (1), their pharmaceutical uses and compositions.

2. claims: 11-13

Ethyl 4-(pyrimidin-2-yl)butanoate and its process of preparation

3. claim: 14

The use of the defined palladium catalyst in a Negishi coupling reaction

INTERNATIONAL SEARCH REPORT

PC1, AB 03/02985

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/445 A61P37/00 C07D401/12 C07D239/26 C07D211/96

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00/46221 A (CARROLL JEFFERY N ; CRESCENZO GARY A DE (US); MISCHKE DEBORAH A (US) 10 August 2000 (2000-08-10) claim 4	1-10
Y	WO 99/24399 A (DARWIN DISCOVERY LTD) 20 May 1999 (1999-05-20) claim 1	1-10
A	WO 00/12478 A (ZENECA PHARMA SA ; TUCKER HOWARD (GB); WATERSON DAVID (GB); ZENECA) 9 March 2000 (2000-03-09) cited in the application claim 1	1-10



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

8 October 2003

Date of mailing of the international search report

02.02.04

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Johnson, C

INTERNATIONAL SEARCH REPORT

In tional application No.
PCT/GB 03/02985

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 8 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-10

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No

P IB 03/02985

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0046221	A	10-08-2000	
		AU 2757400 A	25-08-2000
		BG 105788 A	28-02-2002
		BR 0008440 A	26-03-2002
		CA 2362230 A1	10-08-2000
		CN 1362954 T	07-08-2002
		CZ 20012849 A3	15-05-2002
		EE 200100410 A	16-12-2002
		EP 1157021 A1	28-11-2001
		HU 0200119 A2	29-06-2002
		JP 2002536373 T	29-10-2002
		NO 20013850 A	19-09-2001
		PL 350193 A1	18-11-2002
		SK 11352001 A3	10-09-2002
		WO 0046221 A1	10-08-2000
		US 6492367 B1	10-12-2002
		US 6448250 B1	10-09-2002
		US 6372758 B1	16-04-2002
		ZA 200106492 A	07-05-2003
WO 9924399	A	20-05-1999	
		AT 231837 T	15-02-2003
		AU 748843 B2	13-06-2002
		AU 1046999 A	31-05-1999
		BR 9814147 A	03-10-2000
		CA 2308359 A1	20-05-1999
		CN 1283183 T	07-02-2001
		DE 69811111 D1	06-03-2003
		DE 69811111 T2	24-07-2003
		DK 1030836 T3	26-05-2003
		EP 1030836 A1	30-08-2000
		ES 2190115 T3	16-07-2003
		WO 9924399 A1	20-05-1999
		HU 0100152 A2	28-02-2002
		JP 2001522832 T	20-11-2001
		NO 20002440 A	11-05-2000
		NZ 504387 A	25-10-2002
		PL 340551 A1	12-02-2001
		RU 2210567 C2	20-08-2003
		US 6187924 B1	13-02-2001
		ZA 9810360 A	12-11-1999
WO 0012478	A	09-03-2000	
		AU 764367 B2	14-08-2003
		AU 5524799 A	21-03-2000
		BG 105369 A	31-12-2001
		BR 9913255 A	22-05-2001
		CA 2339761 A1	09-03-2000
		CN 1324347 T	28-11-2001
		EE 200100106 A	17-06-2002
		EP 1109787 A1	27-06-2001
		WO 0012478 A1	09-03-2000
		HU 0103344 A2	28-02-2002
		ID 28786 A	05-07-2001
		JP 2002523493 T	30-07-2002
		NO 20011023 A	25-04-2001
		NZ 509730 A	30-05-2003
		PL 346344 A1	11-02-2002
		SK 2702001 A3	06-08-2001
		TR 200100605 T2	21-08-2001
		ZA 200101231 A	13-05-2002

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-10

Compounds of formula (1), their pharmaceutical uses and compositions.

2. claims: 11-13

Ethyl 4-(pyrimidin-2-yl)butanoate and its process of preparation

3. claim: 14

The use of the defined palladium catalyst in a Negishi coupling reaction
